Chlamydia antigens and corresponding DNA fragments and uses thereof

ABSTRACT

In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically  C. pneumoniae , employing a vector, containing a nucleotide sequence encoding a lorf2 protein of a strain of  Chlamydia pneumoniae  and a promoter to effect expression of the lorf2 gene in the host. Modifications are possible within the scope of this invention.

RELATED U.S. APPLICATION

This present patent application is a Divisional of Ser. No. 09/427,501,filed Oct. 26, 1999, now U.S. Pat. No. 6,403,101, which claims priorityto the following U.S. provisional applications: U.S. Ser. Nos.60/106,037, filed Oct. 28, 1998 and No. 60/154,658, filed Sep. 20, 1999,each incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to Chlamydia antigens and correspondingDNA molecules, which can be used in methods to prevent and treat diseasecaused by Chlamydia infection in mammals, such as humans.

BACKGROUND OF THE INVENTION

Chlamydiae are prokaryotes. They exhibit morphologic and structuralsimilarities to Gram negative bacteria including a trilaminar outermembrane, which contains lipopolysaccharide and several membraneproteins. Chlamydiae are differentiated from other bacteria by theirmorphology and by a unique developmental cycle. They are obligateintracellular parasites with a unique biphasic life cycle consisting ofa metabolically inactive but infectious extracellular stage and areplicating but non-infectious intracellular stage. The replicativestage of the life-cycle takes place within a membrane-bound inclusionwhich sequesters the bacteria away from the cytoplasm of the infectedhost cell.

Because chlamydiae are small and multiply only within susceptible cellsthey were long thought to be viruses. However, they have manycharacteristics in common with other bacteria: (1) they contain both DNAand RNA, (2) they divide by binary fission, (3) their cell envelopesresemble those of other Gram-negative bacteria, (4) they containribosomes similar to those of other bacteria, and (5) they aresusceptible to various antibiotics. Chlamydiae can be seen in the lightmicroscope, and the genome is about one-third the size of theEscherichia coli genome.

Many different strains of chlamydiae have been isolated from birds, man,and other mammals, and these strains can be distinguished on the basisof host range, virulence, pathogenesis, and antigenic composition. Thereis strong homology of DNA within each species, but surprisingly littlebetween species, suggesting long-standing evolutionary separation.

C. trachomatis has a high degree of host specificity, being almostcompletely limited to man; it causes ocular and genitourinary infectionsof widely varying severity. In contrast, C. psittaci strains are rare inman but are found in a wide range of birds and also in wild, domestic,and laboratory mammals, where they multiply in cells of many organs.

C. pneumoniae is a common human pathogen, originally described as theTWAR strain of C. psittaci, but subsequently recognized to be a newspecies. C. pneumoniae is antigenically, genetically, andmorphologically distinct from other Chlamydia species (C. trachomatis,C. pecorum and C. psittaci). It shows 10% or less DNA sequence homologywith either of C. trachomatis or C. psittaci and so far appears toconsist of only a single strain, TWAR.

C. pneumoniae is a common cause of community acquired pneumonia, lessfrequent only than Streptococcus pneumoniae and Mycoplasma pneumoniae.Grayston et al., J. Infect. Dis. 168: 1231 (1995); Campos et al.,Invest. Ophthalmol. Vis. Sci. 36: 1477 (1995), each incorporated hereinby reference. It can also cause upper respiratory tract symptoms anddisease, including bronchitis and sinusitis. See, e.g., Grayston et al.,J. Infect. Dis. 168: 1231 (1995); Campos et al., Invest. Ophthalmol.Vis. Sci. 36: 1477 (1995); Grayston et al., J. Infect. Dis. 161: 618(1990); Marrie, Clin. Infect. Dis. 18: 501 (1993). The great majority ofthe adult population (over 60%) has antibodies to C. pneumoniae (Wang etal., Chlamydial Infections, Cambridge University Press, Cambridge, p.329 (1986)), indicating past infection which was unrecognized orasymptomatic.

C. pneumoniae infection usually presents as an acute respiratory disease(i.e., cough, sore throat, hoarseness, and fever; abnormal chest soundson auscultation). For most patients, the cough persists for 2 to 6weeks, and recovery is slow. In approximately 10% of these cases, upperrespiratory tract infection is followed by bronchitis or pneumonia.Furthermore, during a C. pneumoniae epidemic, subsequent co-infectionwith pneumococcus has been noted in about half of these pneumoniapatients, particularly in the infirm and the elderly. As noted above,there is more and more evidence that C. pneumoniae infection is alsolinked to diseases other than respiratory infections.

The reservoir for the organism is presumably people. In contrast to C.psittaci infections, there is no known bird or animal reservoir.Transmission has not been clearly defined. It may result from directcontact with secretions, from formites, or from airborne spread. Thereis a long incubation period, which may last for many months. Based onanalysis of epidemics, C. pneumoniae appears to spread slowly through apopulation (case-to-case interval averaging 30 days) because infectedpersons are inefficient transmitters of the organism. Susceptibility toC. pneumoniae is universal. Reinfections occur during adulthood, tofollowing the primary infection as a child. C. pneumoniae appears to bean endemic disease throughout the world, noteworthy for superimposedintervals of increased incidence (epidemics) that persist for 2 to 3years. C. trachomatis infection does not confer cross-immunity to C.pneumoniae. Infections are easily treated with oral antibiotics,tetracycline or erythromycin (2 g/day, for at least 10 to 14 days). Arecently developed drug, azithromycin, is highly effective as asingle-dose therapy against chlamydial infections.

In most instances, C. pneumoniae infection is mild and withoutcomplications, and up to 90% of infections are subacute or unrecognized.Among children in industrialized countries, infections have been thoughtto be rare up to the age of five years, although a recent study hasreported that many children in this age group show PCR evidence ofinfection despite being seronegative, and estimates a prevalence of17-19% in 2-4 years old. See, Normann et al., Acta Paediatrica, 87:23-27 (1998). In developing countries, the seroprevalence of C.pneumoniae antibodies among young children is elevated, and there aresuspicions that C. pneumoniae may be an important cause of acute lowerrespiratory tract disease and mortality for infants and children intropical regions of the world.

From seroprevalence studies and studies of local epidemics, the initialC. pneumoniae infection usually happens between the ages of 5 and 20years. In the USA, for example, there are estimated to be 30,000 casesof childhood pneumonia each year caused by C. pneumoniae. Infections maycluster among groups of children or young adults (e.g., school pupils ormilitary conscripts).

C. pneumoniae causes 10 to 25% of community-acquired lower respiratorytract infections (as reported from Sweden, Italy, Finland, and the USA).During an epidemic, C. pneumonia infection may account for 50 to 60% ofthe cases of pneumonia. During these periods, also, more episodes ofmixed infections with S. pneumoniae have been reported.

Reinfection during adulthood is common; the clinical presentation tendsto be milder. Based on population seroprevalence studies, there tends tobe increased exposure with age, which is particularly evident among men.Some investigators have speculated that a persistent, asymptomatic C.pneumoniae infection state is common.

In adults of middle age or older, C. pneumoniae infection may progressto chronic bronchitis and sinusitis. A study in the USA revealed thatthe incidence of pneumonia caused by C. pneumoniae in persons youngerthan 60 years is 1 case per 1,000 persons per year; but in the elderly,the disease incidence rose three-fold. C. pneumoniae infection rarelyleads to hospitalization, except in patients with an underlying illness.

Of considerable importance is the association of atherosclerosis and C.pneumoniae infection. There are several epidemiological studies showinga correlation of previous infections with C. pneumoniae and heartattacks, coronary artery and carotid artery disease. See, Saikku et al.,Lancet 2: 983 (1988); Thom et al., JAMA 268: 68 (1992);. Linnanmaki etal., Circulation 87: 1030 (1993); Saikku et al., Annals Int. Med. 116:273 (1992); Melnick et al., Am. J. Med. 95: 499 (1993). Moreover, theorganisms has been detected in atheromas and fatty streaks of thecoronary, carotid, peripheral arteries and aorta. See, Shor et al.,South African Med. J. 82: 158 (1992); Kuo et al., J. Infect. Dis. 167:841 (1993); Kuo et al., Arteriosclerosis and Thrombosis 13: 1500 (1993);Campbell et al., J. Infect. Dis. 172: 585 (1995); Chiu et al.,Circulation 96: 2144-2148 (1997). Viable C. pneumoniae has beenrecovered from the coronary and carotid artery. Ramirez et al., AnnalsInt. Med. 125: 979 (1996); Jackson et al., Abst. K121, p272, 36th ICAAC,New Orleans (1996). Furthermore, it has been shown that C. pneumoniaecan induce changes of atherosclerosis in a rabbit model. See, Fong etal., (1997) Journal of Clinical Microbiolology 35: 48. Taken together,these results indicate that it is highly probable that C. pneumoniae cancause atherosclerosis in humans, though the epidemiological importanceof chlamydial atherosclerosis remains to be demonstrated.

A number of recent studies have also indicated an association between C.pneumoniae infection and asthma. Infection has been linked to wheezing,asthmatic bronchitis, adult-onset asthma and acute exacerbation ofasthma in adults, and small-scale studies have shown that prolongedantibiotic treatment was effective at greatly reducing the severity ofthe disease in some individuals. Hahn et al., Ann Allergy AsthmaImmunol. 80: 45-49 (1998); Hahn et al., Epidemiol Infect. 117: 513-517(1996); Bjornsson et al., Scand J. Infect. Dis. 28: 63-69 (1996); Hahn,J. Fam. Pract. 41: 345-351 (1995); Allegra et al., Eur. Respir. J. 7:2165-2168 (1994); Hahn et al., JAMA 266: 225-230 (1991).

In light of these results, a protective vaccine against disease causedby C. pneumoniae infection would be of considerable importance. There isnot yet an effective vaccine for human C. pneumoniae infection.Nevertheless, studies with C. trachomatis and C. psittaci indicate thatthis is an attainable goal. For example, mice which have recovered froma lung infection with C. trachomatis are protected from infertilityinduced by a subsequent vaginal challenge. Pal et al., Infection andImmunity 64: 5341 (1996). Similarly, sheep immunized with inactivated C.psittaci were protected from subsequent chlamydial-induced abortions andstillbirths. Jones et al., Vaccine 13: 715 (1995). Protection fromchlamydial infections has been associated with Th1 immune responses,particularly the induction of INFγ-producing CD4+ T cells. Igietsemes etal., Immunology 5: 317 (1993). The adoptive transfer of CD4+ cell linesor clones to nude or SCID mice conferred protection from challenge orcleared chronic disease (Igietseme et al., Regional Immunology 5: 317(1993); Magee et al., Regional Immunology 5: 305 (1993)), and in vivodepletion of CD4+ T cells exacerbated disease post-challenge (Landers etal., Infection & Immunity 59: 3774 (1991); Magee et al., Infection &Immunity 63: 516 (1995)). However, the presence of sufficiently hightitres of neutralizing antibody at mucosal surfaces can also exert aprotective effect. Cotter et al., Infection and Immunity 63: 4704(1995).

The extent of antigenic variation within the species C. pneumoniae isnot well characterized. Serovars of C. trachomatis are defined on thebasis of antigenic variation in major outer membrane proteins (MOMP),but published C. pneumoniae MOMP gene sequences show no variationbetween several diverse isolates of the organism. See, Campbell et al.,Infection and Immunity 58: 93 (1990); McCafferty et al., Infection andImmunity 63: 2387-9 (1995); Knudsen et al., Third Meeting of theEuropean Society for Chlamydia Research, Vienna (1996). Regions of theprotein known to be conserved in other chlamydial MOMPs are conserved inC. pneumoniae. See, Campbell et al., Infection and Immunity 58: 93(1990); McCafferty et al., Infection and Immunity 63: 2387-9 (1995). Onestudy has described a strain of C. pneumoniae with a MOMP of greaterthat usual molecular weight, but the gene for this has not beensequenced. Grayston et al., J. Infect. Dis. 168: 1231 (1995). Partialsequences of outer membrane protein 2 from nine diverse isolates werealso found to be invariant. Ramirez et al., Annals Int. Med. 125: 979(1996). The genes for HSP60 and HSP70 show little variation from otherchlamydial species, as would be expected. The gene encoding a 76 kDaantigen has been cloned from a single strain of C. pneumoniae. It has nosignificant similarity with other known chlamydial genes. Marrie, Clin.Infect. Dis. 18: 501 (1993).

Many antigens recognized by immune sera to C. pneumoniae are conservedacross all chlamydiae, but 98 kDa, 76 kDa and 54 kDa proteins may be C.pneumoniae-specific. Campos et al., Invest. Ophthalmol. Vis. Sci. 36:1477 (1995); Marrie, Clin. Infect. Dis. 18: 501 (1993);Wiedmann-Al-Ahmad et al., Clin. Diagn. Lab. Immunol. 4: 700-704 (1997).Immunoblotting of isolates with sera from patients does show variationof blotting patterns between isolates, indicating that serotypes C.pneunioniae may exist. Grayston et al., J. Infect. Dis. 168: 1231(1995); Ramirez et al., Annals Int. Med. 125: 979 (1996). However, theresults are potentially confounded by the infection status of thepatients, since immunoblot profiles of a patient's sera change with timepost-infection. An assessment of the number and relative frequency ofany serotypes, and the defining antigens, is not yet possible.

Thus, a need remains for effective compositions for preventing,treating, and diagnosing Chlamydia infections.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides purified and isolated DNAmolecules that encode Chlamydia which can be used in methods to prevent,treat, and diagnose Chlamydia infection. Encoded polypeptides,designated lorf2, include polypeptides having the amino acid sequenceshown in SEQ ID NO: 2 and the DNA molecules include SEQ ID NO: 1full-length sequence (top sequence) and coding sequence (bottomsequence) for the mature polypeptide. Those skilled in the art willappreciate that the invention also includes DNA molecules that encodemutants, variants, and derivatives of such polypeptides, which resultfrom the addition, deletion, or substitution of non-essential aminoacids as described herein. The invention also includes RNA moleculescorresponding to the DNA molecules of the invention.

In addition to the DNA and RNA molecules, the invention includes thecorresponding polypeptides and monospecific antibodies that specificallybind to such polypeptides.

The present invention has wide application and includes expressioncassettes, vectors, and cells transformed or transfected with thepolynucleotides of the invention. Accordingly, the present inventionprovides (i) a method for producing a polypeptide of the invention in arecombinant host system and related expression cassettes, vectors, andtransformed or transfected cells; (ii) a live vaccine vectors such asviral or bacterial live vaccine vectors, including, pox virus,alphavirus, Salmonella typhimurium, or Vibrio cholerae vector,containing a polynucleotide of the invention, such vaccine vectors beinguseful for, e.g., preventing and treating Chlamydia infection, incombination with a diluent or carrier, and related pharmaceuticalcompositions and associated therapeutic and/or prophylactic methods;(iii) a therapeutic and/or prophylactic method involving administrationof an RNA or DNA molecule of the invention, either in a naked form orformulated with a delivery vehicle, a polypeptide or combination ofpolypeptides, or a monospecific antibody of the invention, and relatedpharmaceutical compositions; (iv) a method for diagnosing the presenceof Chlamydia in a biological sample, which can involve the use of a DNAor RNA molecule, a monospecific antibody, or a polypeptide of theinvention; and (v) a method for purifying a polypeptide of the inventionby antibody-based affinity chromatography. The present inventionprovides purified and isolated DNA molecules, which encode Chlamydiathat can be used in methods to prevent, treat, and diagnose Chlamydiainfection.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be further understood from the followingdescription with reference to the drawings, in which:

FIGS. 1A-1C shows the nucleotide sequence (top sequence) (SEQ ID NO: 1)and the deduced amino acid sequence (bottom sequence) (SEQ ID NO: 2) ofthe full-length lorf2 gene from Chlamydia pneumoniae.

FIGS. 2A-2F shows the restriction enzyme analysis of nucleotide sequenceencoding the C. pneumoniae lorf2 gene (SEQ ID NO: 1) and its reversecomplement (SEQ ID NO:5).

FIG. 3 shows the construction and elements of plasmid pCAI556.

FIG. 4 illustrates protection against C. pneumoniae infection by pCAI556following DNA immunization. Individual data points are shown for eachanimal (hollow diamonds) as well as mean and standard deviation for eachgroup (solid squares).

DETAILED DESCRIPTION OF THE INVENTION

In the C. pneumoniae genome, open reading frames (ORFs) encodingchlamydial polypeptides have been identified. These polypeptides includepolypeptides permanently found in the bacterial membrane structure,polypeptides that are present in the external vicinity of the bacterialmembrane, polypeptides permanently found in the inclusion membranestructure, polypeptides that are present in the external vicinity of theinclusion membrane, and polypeptides that are released into thecytoplasm of the infected cell. These polypeptides can be used invaccination methods for preventing and treating Chlamydia infection.

According to a first aspect of the invention, there are providedisolated polynucleotides encoding the precursor and mature forms ofChlamydia polypeptides.

An isolated polynucleotide of the invention encodes a polypeptide havingan amino acid sequence that is homologous to a Chlamydia amino acidsequence, the Chlamydia amino acid sequence being selected from thegroup consisting of the amino acid sequences as shown in SEQ ID NOS: 1and 2. Comparison of the sequence of this gene as to the recentlypublished genome sequence of C. pneumoniae reveals that the sequenceactually contains at least two open reading frames, a first one in the5′ portion and a second one in the 3′ portion of the sequence. Despitethe presence of the stop codon at the end of SEQ ID 1, C. pneumoniaedoes make a 76 kDa product. Thus, it appears possible that C. pneumoniaeis able to read through this stop codon and produce a full lengthproduct terminated by the stop codon at the end of the second openreading frame. Furthermore, analysis of the genome sequence indicatesthat there is at least one in-frame ATG upstream of the start codon.This suggests that the first open reading frame may form part of one ormore larger open reading frames. Seehttp://chlamydia-www.berkeley.edu:4231/.

The term “isolated polynucleotide” is defined as a polynucleotideremoved from the environment in which it naturally occurs. For example,a naturally-occurring DNA molecule present in the genome of a livingbacteria or as part of a gene bank is not isolated, but the samemolecule separated from the remaining part of the bacterial genome, as aresult of, e.g., a cloning event (amplification), is isolated.Typically, an isolated DNA molecule is free from DNA regions (e.g.,coding regions) with which it is immediately contiguous at the 5′ or 3′end, in the naturally occurring genome. Such isolated polynucleotidescould be part of a vector or a composition and still be isolated in thatsuch a vector or composition is not part of its natural environment.

A polynucleotide of the invention can be in the form of RNA or DNA(e.g., cDNA, genomic DNA, or synthetic DNA), or modifications orcombinations thereof. The DNA can be double-stranded or single-stranded,and, if single-stranded, can be the coding strand or the non-coding(anti-sense) strand. The sequence that encodes a polypeptide of theinvention as shown in SEQ ID NO: 1 can be (a) the coding sequence(bottom sequence); (b) a ribonucleotide sequence derived bytranscription of (a); or (c) a different coding sequence. This latter,as a result of the redundancy or degeneracy of the genetic code, encodesthe same polypeptides as the DNA molecules of which the nucleotidesequences are illustrated in SEQ ID NOS: 1 or2.

By “homologous amino acid sequence” is meant an amino acid sequence thatdiffers from an amino acid sequence shown in SEQ ID NO: 2, only by oneor more conservative amino acid substitutions, or by one or morenon-conservative amino acid substitutions, deletions, or additionslocated at positions at which they do not destroy the specificantigenicity of the polypeptide.

Preferably, such a sequence is at least 75%, more preferably 80%, andmost preferably 90% identical to an amino acid sequence shown in SEQ IDNO: 2.

Homologous amino acid sequences include sequences that are identical orsubstantially identical to an amino acid sequence as shown in SEQ ID NO:2. By “amino acid sequence substantially identical” is meant a sequencethat is at least 90%, preferably 95%, more preferably 97%, and mostpreferably 99% identical to an amino acid sequence of reference and thatpreferably differs from the sequence of reference, if at all, by amajority of conservative amino acid substitutions.

Conservative amino acid substitutions typically include substitutionsamong amino acids of the same class. These classes include, for example,(a) amino acids having uncharged polar side chains, such as asparagine,glutamine, serine, threonine, and tyrosine; (b) amino acids having basicside chains, such as lysine, arginine, and histidine; (c) amino acidshaving acidic side chains, such as aspartic acid and glutamic acid; and(d) amino acids having nonpolar side chains, such as glycine, alanine,valine, leucine, isoleucine, proline, phenylalanine, methionine,tryptophan, and cysteine.

Homology is typically measured using sequence analysis software (e.g.,Sequence Analysis Software Package of the Genetics Computer Group,University of Wisconsin Biotechnology Center, 1710 University Avenue,Madison, Wis. 53705). Similar amino acid sequences are aligned to obtainthe maximum degree of homology (i.e., identity). To this end, it may benecessary to artificially introduce gaps into the sequence. Once theoptimal alignment has been set up, the degree of homology (i.e.,identity) is established by recording all of the positions in which theamino acids of both sequences are identical, relative to the totalnumber of positions.

Similarity factors include similar size, shape and electrical charge.One particularly preferred method of determining amino acid similaritiesis the PAM250 matrix described in Dayhoffet et al., 5 Atlas of ProteinSequence and Structure 345-352 (1978 & Supp.), incorporated by referenceherein. A similarity score is first calculated as the sum of the alignedpairwise amino acid similarity scores. Insertions and deletions areignored for the purposes of percent homology and identity. Accordingly,gap penalties are not used in this calculation. The raw score is thennormalized by dividing it by the geometric mean of the scores of thecandidate compound and the reference sequence. The geometric mean is thesquare root of the product of these scores. The normalized raw score isthe percent homology.

Preferably, a homologous sequence is one that is at least 45%, morepreferably 60%, and most preferably 85% identical to the coding sequenceof SEQ ID NO: 1.

Polypeptides having a sequence homologous to one of the sequences shownin SEQ ID NOS: 1 and 2, include naturally-occurring allelic variants, aswell as mutants and variants or any other non-naturally-occurringvariants that are analogous in terms of antigenicity, to a polypeptidehaving a sequence as shown in SEQ ID NOS: 1 or 2.

An allelic variant is an alternate form of a polypeptide that ischaracterized as having a substitution, deletion, or addition of one ormore amino acids that does not substantially alter the biologicalfunction of the polypeptide. By “biological function” is meant thefunction of the polypeptide in the cells in which it naturally occurs,even if the function is not necessary for the growth or survival of thecells. For example, the biological function of a porin is to allow theentry into cells of compounds present in the extracellular medium. Thebiological function is distinct from the antigenic function. Apolypeptide can have more than one biological function.

Allelic variants are very common in nature. For example, a bacterialspecies, e.g., C. pneumoniae, is usually represented by a variety ofstrains that differ from each other by minor allelic variations. Indeed,a polypeptide that fulfills the same biological function in differentstrains can have an amino acid sequence that is not identical in each ofthe strains. Such an allelic variation may be equally reflected at thepolynucleotide level.

Support for the use of allelic variants of polypeptide antigens comesfrom, e.g., studies of the Chlamydial MOMP antigen. The amino acidsequence of the MOMP varies from strain to strain, yet cross-strainantibody binding plus neutralization of infectivity occurs, indicatingthat the MOMP, when used as an immunogen, is tolerant of amino acidvariations.

Polynucleotides, e.g., DNA molecules, encoding allelic variants caneasily be retrieved by polymerase chain reaction (PCR) amplification ofgenomic bacterial DNA extracted by conventional methods. This involvesthe use of synthetic oligonucleotide primers matching upstream anddownstream of the 5′ and 3′ ends of the encoding domain. Suitableprimers can be designed according to the nucleotide sequence informationprovided in SEQ ID NOS: 1 and 2. Typically, a primer can consist of 10to 40, preferably 15 to 25 nucleotides. It may be also advantageous toselect primers containing C and G nucleotides in a proportion sufficientto ensure efficient hybridization; e.g., an amount of C and Gnucleotides of at least 40%, preferably 50% of the total nucleotideamount.

Useful homologs that do not naturally occur can be designed using knownmethods for identifying regions of an antigen that are likely to betolerant of amino acid sequence changes and/or deletions. For example,sequences of the antigen from different species can be compared toidentify conserved sequences.

Polypeptide derivatives that are encoded by polynucleotides of theinvention include, e.g., fragments, polypeptides having large internaldeletions derived from full-length polypeptides, and fusion proteins.

Polypeptide fragments of the invention can be derived from a polypeptidehaving a sequence homologous to any of the sequences shown in SEQ IDNOS: 1 and 2, to the extent that the fragments retain the desiredsubstantial antigenicity of the parent polypeptide (specificantigenicity). Polypeptide derivatives can also be constructed by largeinternal deletions that remove a substantial part of the parentpolypeptide, while retaining the desired specific antigenicity.Generally, polypeptide derivatives should be about at least 12 aminoacids in length to maintain the antigenicity. Advantageously, they canbe at least 20 amino acids, preferably at least 50 amino acids, morepreferably at least 75 amino acids, and most preferably at least 100amino acids in length.

Useful polypeptide derivatives, e.g., polypeptide fragments, can bedesigned using computer-assisted analysis of amino acid sequences inorder to identify sites in protein antigens having potential assurface-exposed, antigenic regions. Hughes et al., Infect. Immun. 60:3497 (1992).

Polypeptide fragments and polypeptides having large internal deletionscan be used for revealing epitopes that are otherwise masked in theparent polypeptide and that may be of importance for inducing, forexample, a protective T cell-dependent immune response. Deletions canalso remove immunodominant regions of high variability among strains.

It is an accepted practice in the field of immunology to use fragmentsand variants of protein immunogens as vaccines and immunogens, as allthat is required to induce an immune response to a protein may be asmall (e.g., 8 to 10 amino acid) region of the protein. This has beendone for a number of vaccines against pathogens other than Chlamydia.For example, short synthetic peptides corresponding to surface-exposedantigens of pathogens such as murine mammary tumor virus, peptidecontaining 11 amino acids (Dion et al., Virology 179: 474-477 (1990));Semliki Forest virus, peptide containing 16 amino acids (Snijders etal., J. Gen. Virol. 72: 557-565 (1991)); and canine parvovirus, twooverlapping peptides, each containing 15 amino acids (Langeveld et al.,Vaccine 12: 1473-1480 (1994)) have been shown to be effective vaccineantigens against their respective pathogens.

Polynucleotides encoding polypeptide fragments and polypeptides havinglarge internal deletions can be constructed using standard methods (see,e.g., Ausubel et al., Current Protocols in Molecular Biology, John Wiley& Sons Inc. (1994)); for example, by PCR, including inverse PCR, byrestriction enzyme treatment of the cloned DNA molecules, or by themethod of Kunkel et al. (Proc. Natl. Acad. Sci. USA 82: 448 (1985));biological material available at Stratagene.

A polypeptide derivative can also be produced as a fusion polypeptidethat contains a polypeptide or a polypeptide derivative of the inventionfused, e.g., at the N- or C-terminal end, to any other polypeptide. Forconstruction of DNA encoding the amino acid sequence corresponding tohybrid fusion proteins, a first DNA encoding amino acid sequencecorresponding to portions of SEQ ID NO: 1 or 2 is joined to a second DNAusing methods described in, for example, U.S. Pat. No. 5,844,095,incorporated herein by reference. A product can then be easily obtainedby translation of the genetic fusion. Vectors for expressing fusionpolypeptides are commercially available, such as the pMal-c2 or pMal-p2systems of New England Biolabs, in which the fusion peptide is a maltosebinding protein, the glutathione-S-transferase system of Pharmacia, orthe His-Tag system available from Novagen. These and other expressionsystems provide convenient means for further purification ofpolypeptides and derivatives of the invention.

Another particular example of fusion polypeptides included in theinvention includes a polypeptide or polypeptide derivative of theinvention fused to a polypeptide having adjuvant activity, such as,e.g., the subunit B of either cholera toxin or E. coli heat-labiletoxin. Several possibilities are can be used for achieving fusion.First, the polypeptide of the invention can be fused to the N-, orpreferably, to the C-terminal end of the polypeptide having adjuvantactivity. Second, a polypeptide fragment of the invention can be fusedwithin the amino acid sequence of the polypeptide having adjuvantactivity.

As stated above, the polynucleotides of the invention encode Chlamydiapolypeptides in precursor or mature form. They can also encode hybridprecursors containing heterologous signal peptides, which can matureinto polypeptides of the invention. By “heterologous signal peptide” ismeant a signal peptide that is not found in the naturally-occurringprecursor of a polypeptide of the invention.

A polynucleotide of the invention, having a homologous coding sequence,hybridizes, preferably under stringent conditions, to a polynucleotidehaving a sequence as shown in SEQ ID NO: 1. Hybridization procedures aredescribed in, e.g., Ausubel et al., Current Protocols in MolecularBiology, John Wiley & Sons Inc. (1994); Silhavy et al., Experiments WithGene Fusions, Cold Spring Harbor Laboratory Press (1984); Davis et al.,A Manual for Genetic Engineering: Advanced Bacterial Genetics, ColdSpring Harbor Laboratory Press (1980), each incorporated herein byreference. Important parameters that can be considered for optimizinghybridization conditions are reflected in a formula that allowscalculation of a critical value, the melting temperature above which twocomplementary DNA strands separate from each other. Casey and Davidson,Nucl. Acid Res. 4: 1539 (1977). This formula is as follows:

 Tm=81.5+0.5×(%G+C)+1.6 log (positive ion concentration)−0.6×(%formamide).

Under appropriate stringency conditions, hybridization temperature (Th)is approximately 20-40° C., 20-25° C. or, preferably, 30-40° C. belowthe calculated Tm. Those skilled in the art will understand that optimaltemperature and salt conditions can be readily determined empirically inpreliminary experiments using conventional procedures.

For example, stringent conditions can be achieved, both forpre-hybridizing and hybridizing incubations, (i) within 4-16 hours at42° C., in 6×SSC containing 50% formamide or (ii) within 4-16 hours at65° C. in an aqueous 6×SSC solution (1 M NaCl, 0.1 M sodium citrate (pH7.0)).

For polynucleotides containing 30 to 600 nucleotides, the above formulais used and then is corrected by subtracting (600/polynucleotide size inbase pairs). Stringency conditions are defined by a Th that is 5 to 10°C. below Tm.

Hybridization conditions with oligonucleotides shorter than 20-30 basesdo not exactly follow the rules set forth above. In such cases, theformula for calculating the Tm is as follows:

Tm=4×(G+C)+2(A+T).

For example, an 18 nucleotide fragment of 50% G+C would have anapproximate Tm of 54° C.

A polynucleotide molecule of the invention, containing RNA, DNA, ormodifications or combinations thereof, can have various applications.For example, a DNA molecule can be used (i) in a process for producingthe encoded polypeptide in a recombinant host system, (ii) in theconstruction of vaccine vectors such as poxviruses, which are furtherused in methods and compositions for preventing and/or treatingChlamydia infection, (iii) as a vaccine agent (as well as an RNAmolecule), in a naked form or formulated with a delivery vehicle and,(iv) in the construction of attenuated Chlamydia strains that canoverexpress a polynucleotide of the invention or express it in amodified, mutated form, such as a non-toxic form, if appropriate. Forvaccine compositions and uses of the proteins and peptides and encodingnucleotides of the present invention for protection against diseasescaused by Chlamydia, it is not preferred to use naked DNA encoding theprotein or peptides and administering these nucleotides intranasally orintramuscularly. For these proteins, it is preferred to administer theencoding nucleic acids by other routes such as intradermally and/or toformulate the encoding nucleic acids to improve (or adjuvant) the immuneresponse. It is also preferred to include the encoding nucleic acid aspart of a recombinant live vector, such as a viral or bacterial vectorfor use as the immunizing agent. It is also preferred to immunize withvaccine formulations comprising the proteins or peptides of theinvention themselves. These vaccine formulations may include the use ofadjuvants.

According to a second aspect of the invention, there is thereforeprovided (i) an expression cassette containing a DNA molecule of theinvention placed under the control of the elements required forexpression, in particular under the control of an appropriate promoter;(ii) an expression vector containing an expression cassette of theinvention; (iii) a prokaryotic or eukaryotic cell transformed ortransfected with an expression cassette and/or vector of the invention,as well as (iv) a process for producing a polypeptide or polypeptidederivative encoded by a polynucleotide of the invention, which involvesculturing a prokaryotic or eukaryotic cell transformed or transfectedwith an expression cassette and/or vector of the invention, underconditions that allow expression of the DNA molecule of the inventionand, recovering the encoded polypeptide or polypeptide derivative fromthe cell culture.

A recombinant expression system can be selected from prokaryotic andeukaryotic hosts. Eukaryotic hosts include yeast cells (e.g.,Saccharomyces cerevisiae or Pichia pastoris), mammalian cells (e.g.,COS1, NIH3T3, or JEG3 cells), arthropods cells (e.g., Spodopterafrugiperda (SF9) cells), and plant cells. Preferably, a prokaryotic hostsuch as E. coli is used. Bacterial and eukaryotic cells are availablefrom a number of different sources to those skilled in the art, e.g.,the American Type Culture Collection (ATCC; Rockville, Md.).

The choice of the expression system depends on the features desired forthe expressed polypeptide. For example, it may be useful to produce apolypeptide of the invention in a particular lipidated form or any otherform.

The choice of the expression cassette will depend on the host systemselected as well as the features desired for the expressed polypeptide.Typically, an expression cassette includes a promoter that is functionalin the selected host system and can be constitutive or inducible; aribosome binding site; a start codon (ATG) if necessary, a regionencoding a signal peptide, e.g., a lipidation signal peptide; a DNAmolecule of the invention; a stop codon; and optionally a 3′ terminalregion (translation and/or transcription terminator). The signal peptideencoding region is adjacent to the polynucleotide of the invention andplaced in proper reading frame. The signal peptide-encoding region canbe homologous or heterologous to the DNA molecule encoding the maturepolypeptide and can be specific to the secretion apparatus of the hostused for expression. The open reading frame constituted by the DNAmolecule of the invention, solely or together with the signal peptide,is placed under the control of the promoter so that transcription andtranslation occur in the host system. Promoters, signal peptide encodingregions are widely known and available to those skilled in the art andincludes, for example, the promoter of Salmonella typhimurium (andderivatives) that is inducible by arabinose (promoter araB) and isfunctional in Gram-negative bacteria such as E. coli (as described inU.S. Pat. No. 5,028,530 and in Cagnon et al., (Cagnon et al., ProteinEngineering 4: 843 (199 1)); the promoter of the gene of bacteriophageT7 encoding RNA polymerase, that is functional in a number of E. colistrains expressing T7 polymerase (described in U.S. Pat. No. 4,952,496);OspA lipidation signal peptide; and RlpB lipidation signal peptide(Takase et al., J. Bact. 169: 5692 (1987)).

The expression cassette is typically part of an expression vector, whichis selected for its ability to replicate in the chosen expressionsystem. Expression vectors (e.g., plasmids or viral vectors) can bechosen from those described in Pouwels et al. (Cloning Vectors:Laboratory Manual, 85, Supp. 1987). They can be purchased from variouscommercial sources.

Methods for transforming/transfecting host cells with expression vectorswill depend on the host system selected as described in Ausubel et al.,Current Protocols in Molecular Biology, John Wiley & Sons Inc. (1994).

Upon expression, a recombinant polypeptide of the invention (or apolypeptide derivative) is produced and remains in the intracellularcompartment, is secreted/excreted in the extracellular medium or in theperiplasmic space, or is embedded in the cellular membrane. Thepolypeptide can then be recovered in a substantially purified form fromthe cell extract or from the supernatant after centrifugation of therecombinant cell culture. Typically, the recombinant polypeptide can bepurified by antibody-based affinity purification or by any other methodthat can be readily adapted by a person skilled in the art, such as bygenetic fusion to a small affinity binding domain. Antibody-basedaffinity purification methods are also available for purifying apolypeptide of the invention extracted from a Chlamydia strain.Antibodies useful for purifying by immunoaffinity the polypeptides ofthe invention can be obtained as described below.

A polynucleotide of the invention can also be useful in the vaccinefield, e.g., for achieving DNA vaccination. There are two majorpossibilities, either using a viral or bacterial host as gene deliveryvehicle (live vaccine vector) or administering the gene in a free form,e.g., inserted into a plasmid. Therapeutic or prophylactic efficacy of apolynucleotide of the invention can be evaluated as described below.

Accordingly, in a third aspect of the invention, there is provided (i) avaccine vector such as a poxvirus, containing a DNA molecule of theinvention, placed under the control of elements required for expression;(ii) a composition of matter containing a vaccine vector of theinvention, together with a diluent or carrier; particularly, (iii) apharmaceutical composition containing a therapeutically orprophylactically effective amount of a vaccine vector of the invention;(iv) a method for inducing an immune response against Chlamydia in amammal (e.g., a human; alternatively, the method can be used inveterinary applications for treating or preventing Chlamydia infectionof animals, e.g., cats or birds), which involves administering to themammal an immunogenically effective amount of a vaccine vector of theinvention to elicit an immune response, e.g., a protective ortherapeutic immune response to Chlamydia; and particularly, (v) a methodfor preventing and/or treating a Chlamydia (e.g., C. trachomatis, C.psittaci, C. pneumonia, C. pecorum) infection, which involvesadministering a prophylactic or therapeutic amount of a vaccine vectorof the invention to an individual in need. Additionally, the thirdaspect of the invention encompasses the use of a vaccine vector of theinvention in the preparation of a medicament for preventing and/ortreating Chlamydia infection.

A vaccine vector of the invention can express one or severalpolypeptides or derivatives of the invention, as well as at least oneadditional Chlamydia antigen, fragment, homolog, mutant, or derivativethereof. In addition, it can express a cytokine, such as interleukin-2(IL-2) or interleukin-12 (IL-12), that enhances the immune response(adjuvant effect). Thus, a vaccine vector can include an additional DNAsequence encoding, e.g., a chlamydial antigen , or a cytokine, placedunder the control of elements required for expression in a mammaliancell.

Alternatively, a composition of the invention can include severalvaccine vectors, each of them being capable of expressing a polypeptideor derivative of the invention. A composition can also contain a vaccinevector capable of expressing an additional Chlamydia antigen, or asubunit, fragment, homolog, mutant, or derivative thereof; or a cytokinesuch as IL-2 or IL-12.

In vaccination methods for treating or preventing infection in a mammal,a vaccine vector of the invention can be administered by anyconventional route in use in the vaccine field, particularly, to amucosal (e.g., ocular, intranasal, oral, gastric, pulmonary, intestinal,rectal, vaginal, or urinary tract) surface or via the parenteral (e.g.,subcutaneous, intradermal, intramuscular, intravenous, orintraperitoneal) route. Preferred routes depend upon the choice of thevaccine vector. The administration can be achieved in a single dose orrepeated at intervals. The appropriate dosage depends on variousparameters understood by skilled artisans such as the vaccine vectoritself, the route of administration or the condition of the mammal to bevaccinated (weight, age and the like).

Live vaccine vectors available in the art include viral vectors such asadenoviruses, alphavirus, and poxviruses as well as bacterial vectors,e.g., Shigella, Salmonella, Vibrio cholerae, Lactobacillus, Bacillebilié de Calmette-Guérin (BCG), and Streptococcus.

An example of an adenovirus vector, as well as a method for constructingan adenovirus vector capable of expressing a DNA molecule of theinvention, are described in U.S. Pat. No. 4,920,209. Poxvirus vectorsthat can be used include, e.g., vaccinia and canary pox virus, describedin U.S. Pat. No. 4,722,848 and U.S. Pat. No. 5,364,773, respectively(also see, e.g., Tartaglia et al., Virology 188: 217 (1992)) for adescription of a vaccinia virus vector; and Taylor et al, Vaccine 13:539 (1995) for a reference of a canary pox). Poxvirus vectors capable ofexpressing a polynucleotide of the invention can be obtained byhomologous recombination as described in Kieny et al., Nature 312: 163(1984) so that the polynucleotide of the invention is inserted in theviral genome under appropriate conditions for expression in mammaliancells. Generally, the dose of vaccine viral vector, for therapeutic orprophylactic use, can be of from about 1×10⁴ to about 1×10¹¹advantageously from about 1×10⁷ to about 1×10¹⁰, preferably of fromabout 1×10⁷ to about 1×10⁹ plaque-forming units per kilogram.Preferably, viral vectors are administered parenterally; for example, inthree doses, four weeks apart. Those skilled in the art recognize thatit is preferable to avoid adding a chemical adjuvant to a compositioncontaining a viral vector of the invention and thereby minimizing theimmune response to the viral vector itself.

Non-toxicogenic Vibrio cholerae mutant strains that are useful as a liveoral vaccine are described in Mekalanos et al., Nature 306: 551 (1983)and U.S. Pat. No. 4,882,278 (strain in which a substantial amount of thecoding sequence of each of the two ctxA alleles has been deleted so thatno functional cholerae toxin is produced); WO 92/11354 (strain in whichthe irgA locus is inactivated by mutation; this mutation can be combinedin a single strain with ctxA mutations); and WO 94/1533 (deletion mutantlacking functional ctxA and attRS1 DNA sequences). These strains can begenetically engineered to express heterologous antigens, as described inWO 94/19482. An effective vaccine dose of a Vibrio cholerae straincapable of expressing a polypeptide or polypeptide derivative encoded bya DNA molecule of the. invention can contain, e.g., about 1×10⁵ to about1×10⁹, preferably about 1×10⁶ to about 1×10⁸ viable bacteria in anappropriate volume for the selected route of administration. Preferredroutes of administration include all mucosal routes; most preferably,these vectors are administered intranasally or orally.

Attenuated Salmonella typhimurium strains, genetically engineered forrecombinant expression of heterologous antigens or not, and their use asoral vaccines are described in Nakayama et al., Bio/Technology 6: 693(1988) and WO 92/11361. Preferred routes of administration include allmucosal routes; most preferably, these vectors are administeredintranasally or orally.

Others bacterial strains useful as vaccine vectors are described in Highet al., EMBO 11: 1991 (1992); Sizemore et al., Science 270: 299 (1995)(Shigella flexneri); Medaglini et al., Proc. Natl. Acad. Sci. USA 92:6868 (1995) (Streptococcus gordonii); and Flynn, Cell. Mol. Biol. 40: 31(1994), WO 88/6626, WO 90/0594, WO 91/13157, WO 92/1796, and WO 92/21376(Bacille Calmette Guerin).

In bacterial vectors, polynucleotide of the invention can be insertedinto the bacterial genome or can remain in a free state, carried on aplasmid.

An adjuvant can also be added to a composition containing a vaccinebacterial vector. A number of adjuvants are known to those skilled inthe art. Preferred adjuvants can be selected from the list providedbelow.

According to a fourth aspect of the invention, there is also provided(i) a composition of matter containing a polynucleotide of theinvention, together with a diluent or carrier; (ii) a pharmaceuticalcomposition containing a therapeutically or prophylactically effectiveamount of a polynucleotide of the invention; (iii) a method for inducingan immune response against Chlamydia, in a mammal, by administering tothe mammal, an immunogenically effective amount of a polynucleotide ofthe invention to elicit an immune response, e.g., a protective immuneresponse to Chlamydia; and particularly, (iv) a method for preventingand/or treating a Chlamydia (e.g., C. trachomatis, C. psittaci, C.pneumoniae, or C. pecorum) infection, by administering a prophylactic ortherapeutic amount of a polynucleotide of the invention to an individualin need. Additionally, the fourth aspect of the invention encompassesthe use of a polynucleotide of the invention in the preparation of amedicament for preventing and/or treating Chlamydia infection. Thefourth aspect of the invention preferably includes the use of a DNAmolecule placed under conditions for expression in a mammalian cell,e.g., in a plasmid that is unable to replicate in mammalian cells and tosubstantially integrate in a mammalian genome.

Polynucleotides (DNA or RNA) of the invention can also be administeredas such to a mammal for vaccine, e.g., therapeutic or prophylactic,purpose. When a DNA molecule of the invention is used, it can be in theform of a plasmid that is unable to replicate in a mammalian cell andunable to integrate in the mammalian genome. Typically, a DNA moleculeis placed under the control of a promoter suitable for expression in amammalian cell. The promoter can function ubiquitously ortissue-specifically. Examples of non-tissue specific promoters includethe early Cytomegalovirus (CMV) promoter (described in U.S. Pat. No.4,168,062) and the Rous Sarcoma Virus promoter (described in Norton &Coffin, Molec. Cell Biol. 5: 281(1985)). The desmin promoter (Li et al.,Gene 78: 243 (1989), Li & Paulin, J. Biol. Chem. 266: 6562 (1991), andLi & Paulin, J. Biol. Chem. 268: 10403 (1993)) is tissue-specific anddrives expression in muscle cells. More generally, useful vectors aredescribed, i.a., WO 94/21797 and Hartikka et al., Human Gene Therapy 7:1205 (1996).

For DNA/RNA vaccination, the polynucleotide of the invention can encodea precursor or a mature form. When it encodes a precursor form, theprecursor form can be homologous or heterologous. In the latter case, aeukaryotic leader sequence can be used, such as the leader sequence ofthe tissue-type plasminogen factor (tPA).

A composition of the invention can contain one or severalpolynucleotides of the invention. It can also contain at least oneadditional polynucleotide encoding another Chlamydia antigen or afragment, derivative, mutant, or analog thereof. A polynucleotideencoding a cytokine, such as interleukin-2 (IL-2) or interleukin-12(IL-12), can also be added to the composition so that the immuneresponse is enhanced. These additional polynucleotides are placed underappropriate control for expression. Advantageously, DNA molecules of theinvention and/or additional DNA molecules to be included in the samecomposition, can be carried in the same plasmid.

Standard techniques of molecular biology for preparing and purifyingpolynucleotides can be used in the preparation of polynucleotidetherapeutics of the invention. For use as a vaccine, a polynucleotide ofthe invention can be formulated according to various methods.

First, a polynucleotide can be used in a naked form, free of anydelivery vehicles, such as anionic liposomes, cationic lipids,microparticles, e.g., gold microparticles, precipitating agents, e.g.,calcium phosphate, or any other transfection-facilitating agent. In thiscase, the polynucleotide can be simply diluted in a physiologicallyacceptable solution, such as sterile saline or sterile buffered saline,with or without a carrier. When present, the carrier preferably isisotonic, hypotonic, or weakly hypertonic, and has a relatively lowionic strength, such as provided by a sucrose solution, e.g., a solutioncontaining 20% sucrose.

Alternatively, a polynucleotide can be associated with agents thatassist in cellular uptake. It can be, i.a., (i) complemented with achemical agent that modifies the cellular permeability, such asbupivacaine (see, e.g., WO 94/16737), (ii) encapsulated into liposomes,or (iii) associated with cationic lipids or silica, gold, or tungstenmicroparticles.

Anionic and neutral liposomes are well-known in the art (see, e.g.,Liposomes: A Practical Approach, RPC New Ed, IRL press (1990)), for adetailed description of methods for making liposomes) and are useful fordelivering a large range of products, including polynucleotides.

Cationic lipids are also known in the art and are commonly used for genedelivery. Such lipids include Lipofectin™ also known as DOTMA(N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride), DOTAP(1,2-bis(oleyloxy)-3-(trimethylammonio)propane), DDAB(dimethyldioctadecylammonium bromide), DOGS (dioctadecylamidologlycylspermine) and cholesterol derivatives such as DC-Chol (3beta-(N-(N′,N′-dimethyl aminomethane)-carbamoyl) cholesterol). Adescription of these cationic lipids can be found in EP 187,702, WO90/11092, U.S. Pat. No. 5,283,185, WO 91/15501, WO 95/26356, and U.S.Pat. No. 5,527,928. Cationic lipids for gene delivery are preferablyused in association with a neutral lipid such as DOPE (dioleylphosphatidylethanolamine), as described in, e.g., WO 90/11092.

Other transfection-facilitating compounds can be added to a formulationcontaining cationic liposomes. A number of them are described in, e.g.,WO 93/18759, WO 93/19768, WO 94/25608, and WO 95/2397. They include,i.a., spermine derivatives useful for facilitating the transport of DNAthrough the nuclear membrane (see, for example, WO 93/18759) andmembrane-permeabilizing compounds such as GALA, Gramicidine S, andcationic bile salts (see, for example, WO 93/19768).

Gold or tungsten microparticles can also be used for gene delivery, asdescribed in WO 91/359, WO 93/17706, and Tang et al. (Nature 356: 152(1992)). In this case, the microparticle-coated polynucleotides can beinjected via intradermal or intra-epidermal routes using a needlelessinjection device (“gene gun”), such as those described in U.S. Pat. No.4,945,050, U.S. Pat. No. 5,015,580, and WO 94/24263.

The amount of DNA to be used in a vaccine recipient depends, e.g., onthe strength of the promoter used in the DNA construct, theimmunogenicity of the expressed gene product, the condition of themammal intended for administration (e.g., the weight, age, and generalhealth of the mammal), the mode of administration, and the type offormulation. In general, a therapeutically or prophylactically effectivedose from about 1 mg to about 1 μg, preferably, from about 10 μg toabout 800 μg and, more preferably, from about 25 μg to about 250 μg, canbe administered to human adults. The administration can be achieved in asingle dose or repeated at intervals.

The route of administration can be any conventional route used in thevaccine field. As general guidance, a polynucleotide of the inventioncan be administered via a mucosal surface, e.g., an ocular, intranasal,pulmonary, oral, intestinal, rectal, vaginal, and urinary tract surface;or via a parenteral route, e.g., by an intravenous, subcutaneous,intraperitoneal, intradermal, intra-epidermal, or intramuscular route.The choice of the administration route will depend on, e.g., theformulation that is selected. A polynucleotide formulated in associationwith bupivacaine is advantageously administered into muscles. When aneutral or anionic liposome or a cationic lipid, such as DOTMA orDC-Chol, is used, the formulation can be advantageously injected viaintravenous, intranasal (aerosolization), intramuscular, intradermal,and subcutaneous routes. A polynucleotide in a naked form canadvantageously be administered via the intramuscular, intradermal, orsubcutaneous routes.

Although not absolutely required, such a composition can also contain anadjuvant. If so, a systemic adjuvant that does not require concomitantadministration in order to exhibit an adjuvant effect is preferable suchas, e.g., QS21, which is described in U.S. Pat. No. 5,057,546.

The sequence information provided in the present application enables thedesign of specific nucleotide probes and primers that can be useful indiagnosis. Accordingly, in a fifth aspect of the invention, there isprovided a nucleotide probe or primer having a sequence found in orderived by degeneracy of the genetic code from a sequence shown in SEQID NO: 1.

The term “probe” as used in the present application refers to DNA(preferably single stranded) or RNA molecules (or modifications orcombinations thereof) that hybridize under the stringent conditions, asdefined above, to nucleic acid molecules having sequences homologous tothose shown in SEQ ID NOS: 1 and 2, or to a complementary or anti-sensesequence. Generally, probes are significantly shorter than full-lengthsequences shown in SEQ ID NOS: 1 and 2; for example, they can containfrom about 5 to about 100, preferably from about 10 to about 80nucleotides. In particular, probes have sequences that are at least 75%,preferably at least 85%, more preferably 95% homologous to a portion ofa sequence as shown in SEQ ID NOS: 1 and 2 or that are complementary tosuch sequences. Probes can contain modified bases such as inosine,methyl-5-deoxycytidine, deoxyuridine, dimethylamino-5-deoxyuridine, ordiamino-2,6-purine. Sugar or phosphate residues can also be modified orsubstituted. For example, a deoxyribose residue can be replaced by apolyamide (Nielsen et al., Science 254: 1497 (1991)) and phosphateresidues can be replaced by ester groups such as diphosphate, alkyl,arylphosphonate and phosphorothioate esters. In addition, the2′-hydroxyl group on ribonucleotides can be modified by including, e.g.,alkyl groups.

Probes of the invention can be used in diagnostic tests, as capture ordetection probes. Such capture probes can be conventionally immobilizedon a solid support, directly or indirectly, by covalent means or bypassive adsorption. A detection probe can be labelled by a detectionmarker selected from radioactive isotopes; enzymes such as peroxidase,alkaline phosphatase, and enzymes able to hydrolyze a chromogenic,fluorogenic, or luminescent substrate; compounds that are chromogenic,fluorogenic, or luminescent; nucleotide base analogs; and biotin.

Probes of the invention can be used in any conventional hybridizationtechnique, such as dot blot (Maniatis et al., Molecular Cloning: ALaboratory Manual (1982) Cold Spring Harbor Laboratory Press, ColdSpring Harbor, N.Y.), Southern blot (Southern, J. Mol. Biol. 98: 503(1975)), northern blot (identical to Southern blot to the exception thatRNA is used as a target), or the sandwich technique (Dunn et al., Cell12: 23 (1977)). The latter technique involves the use of a specificcapture probe and/or a specific detection probe with nucleotidesequences that at least partially differ from each other.

A primer is usually a probe of about 10 to about 40 nucleotides that isused to initiate enzymatic polymerization of DNA in an amplificationprocess (e.g., PCR), in an elongation process, or in a reversetranscription method. In a diagnostic method involving PCR, primers canbe labelled.

Thus, the invention also encompasses (i) a reagent containing a probe ofthe invention for detecting and/or identifying the presence of Chlamydiain a biological material; (ii) a method for detecting and/or identifyingthe presence of Chlamydia in a biological material, in which (a) asample is recovered or derived from the biological material, (b) DNA orRNA is extracted from the material and denatured, and (c) exposed to aprobe of the invention, for example, a capture, detection probe or both,under stringent hybridization conditions, such that hybridization isdetected; and (iii) a method for detecting and/or identifyng thepresence of Chlamydia in a biological material, in which (a) a sample isrecovered or derived from the biological material, (b) DNA is extractedtherefrom, (c) the extracted DNA is primed with at least one, andpreferably two, primers of the invention and amplified by polymerasechain reaction, and (d) the amplified DNA fragment is produced.

As previously mentioned, polypeptides that can be produced uponexpression of the newly identified open reading frames are usefulvaccine agents.

Therefore, a sixth aspect of the invention features a substantiallypurified polypeptide or polypeptide derivative having an amino acidsequence encoded by a polynucleotide of the invention.

A “substantially purified polypeptide” is defined as a polypeptide thatis separated from the environment in which it naturally occurs and/orthat is free of the majority of the polypeptides that are present in theenvironment in which it was synthesized. For example, a substantiallypurified polypeptide is free from cytoplasmic polypeptides. Thoseskilled in the art will understand that the polypeptides of theinvention can be purified from a natural source, i.e., a Chlamydiastrain, or can be produced by recombinant means.

Homologous polypeptides or polypeptide derivatives encoded bypolynucleotides of the invention can be screened for specificantigenicity by testing cross-reactivity with an antiserum raisedagainst the polypeptide of reference having an amino acid sequence asshown in SEQ ID NOS: 1 and 2. Briefly, a monospecific hyperimmuneantiserum can be raised against a purified reference polypeptide as suchor as a fusion polypeptide, for example, an expression product of MBP,GST, or His-tag systems or a synthetic peptide predicted to beantigenic. The homologous polypeptide or derivative screened forspecific antigenicity can be produced as such or as a fusionpolypeptide. In this latter case and if the antiserum is also raisedagainst a fusion polypeptide, two different fusion systems are employed.Specific antigenicity can be determined according to a number ofmethods, including Western blot (Towbin et al., Proc. Natl. Acad. Sci.USA 76: 4350 (1979)), dot blot, and ELISA, as described below.

In a Western blot assay, the product to be screened, either as apurified preparation or a total E. coli extract, is submitted toSDS-Page electrophoresis as described by Laemmli, Nature 227: 680(1970). After transfer to a nitrocellulose membrane, the material isfurther incubated with the monospecific hyperimmune antiserum diluted inthe range of dilutions from about 1:5 to about 1:5000, preferably fromabout 1:100 to about 1:500. Specific antigenicity is shown once a bandcorresponding to the product exhibits reactivity at any of the dilutionsin the above range.

In an ELISA assay, the product to be screened is preferably used as thecoating antigen. A purified preparation is preferred, although a wholecell extract can also be used. Briefly, about 100 μl of a preparation atabout 10 μg protein/ml are distributed into wells of a 96-wellpolycarbonate ELISA plate. The plate is incubated for 2 hours at 37° C.then overnight at 4° C. The plate is washed with phosphate buffer saline(PBS) containing 0.05% Tween 20 (PBS/Tween buffer). The wells aresaturated with 250 μl PBS containing 1% bovine serum albumin (BSA) toprevent non-specific antibody binding. After 1 hour incubation at 37°C., the plate is washed with PBS/Tween buffer. The antiserum is seriallydiluted in PBS/Tween buffer containing 0.5% BSA. 100 μl of dilutions areadded per well. The plate is incubated for 90 minutes at 37° C., washedand evaluated according to standard procedures. For example, a goatanti-rabbit peroxidase conjugate is added to the wells when specificantibodies were raised in rabbits. Incubation is carried out for 90minutes at 37° C. and the plate is washed. The reaction is developedwith the appropriate substrate and the reaction is measured bycolorimetry (absorbance measured spectrophotometrically). Under theabove experimental conditions, a positive reaction is shown by O.D.values greater than a non immune control serum.

In a dot blot assay, a purified product is preferred, although a wholecell extract can also be used. Briefly, a solution of the product atabout 100 μg/ml is serially two-fold diluted in 50 mM Tris-HCl (pH 7.5).100 μl of each dilution are applied to a nitrocellulose membrane 0.45 μmset in a 96-well dot blot apparatus (Biorad). The buffer is removed byapplying vacuum to the system. Wells are washed by addition of 50 mMTris-HCl (pH 7.5) and the membrane is air-dried. The membrane issaturated in blocking buffer (50 mM Tris-HCl (pH 7.5) 0.15 M NaCl, 10g/L skim milk) and incubated with an antiserum dilution from about 1:50to about 1:5000, preferably about 1:500. The reaction is revealedaccording to standard procedures. For example, a goat anti-rabbitperoxidase conjugate is added to the wells when rabbit antibodies areused. Incubation is carried out 90 minutes at 37° C. and the blot iswashed. The reaction is developed with the appropriate substrate andstopped. The reaction is measured visually by the appearance of acolored spot, e.g., by colorimetry. Under the above experimentalconditions, a positive reaction is shown once a colored spot isassociated with a dilution of at least about 1:5, preferably of at leastabout 1:500.

Therapeutic or prophylactic efficacy of a polypeptide or derivative ofthe invention can be evaluated as described below.

According to a seventh aspect of the invention, there is provided (i) acomposition of matter containing a polypeptide of the invention togetherwith a diluent or carrier; in particular, (ii) a pharmaceuticalcomposition containing a therapeutically or prophylactically effectiveamount of a polypeptide of the invention; (iii) a method for inducing animmune response against Chlamydia in a mammal, by administering to themammal an immunogenically effective amount of a polypeptide of theinvention to elicit an immune response, e.g., a protective immuneresponse to Chlamydia; and particularly, (iv) a method for preventingand/or treating a Chlamydia (e.g., C. trachomatis. C. psittaci, C.pneumoniae, or C. pecorum) infection, by administering a prophylactic ortherapeutic amount of a polypeptide of the invention to an individual inneed. Additionally, the seventh aspect of the invention encompasses theuse of a polypeptide of the invention in the preparation of a medicamentfor preventing and/or treating Chlamydia infection.

The immunogenic compositions of the invention can be administered by anyconventional route in use in the vaccine field, in particular to amucosal (e.g., ocular, intranasal, pulmonary, oral, gastric, intestinal,rectal, vaginal, or urinary tract) surface or via the parenteral (e.g.,subcutaneous, intradermal, intramuscular, intravenous, orintraperitoneal) route. The choice of the administration route dependsupon a number of parameters, such as the adjuvant associated with thepolypeptide. For example, if a mucosal adjuvant is used, the intranasalor oral route will be preferred and if a lipid formulation or analuminum compound is used, the parenteral route will be preferred. Inthe latter case, the subcutaneous or intramuscular route is mostpreferred. The choice can also depend upon the nature of the vaccineagent. For example, a polypeptide of the invention fused to CTB or LTBwill be best administered to a mucosal surface.

A composition of the invention can contain one or several polypeptidesor derivatives of the invention. It can also contain at least oneadditional Chlamydia antigen, or a subunit, fragment, homolog, mutant,or derivative thereof.

For use in a composition of the invention, a polypeptide or derivativethereof can be formulated into or with liposomes, preferably neutral oranionic liposomes, microspheres, ISCOMS, or virus-like-particles (VLPs)to facilitate delivery and/or enhance the immune response. Thesecompounds are readily available to one skilled in the art; for example,see Liposomes: A Practical Approach (supra).

Adjuvants other than liposomes and the like can also be used and areknown in the art. An appropriate selection can conventionally be made bythose skilled in the art, for example, from the list provided below.

Administration can be achieved in a single dose or repeated as necessaryat intervals as can be determined by one skilled in the art. Forexample, a priming dose can be followed by three booster doses at weeklyor monthly intervals. An appropriate dose depends on various parametersincluding the recipient (e.g., adult or infant), the particular vaccineantigen, the route and frequency of administration, the presence/absenceor type of adjuvant, and the desired effect (e.g., protection and/ortreatment), as can be determined by one skilled in the art. In general,a vaccine antigen of the invention can be administered by a mucosalroute in an amount from about 10 μg to about 500 mg, preferably fromabout 1 mg to about 200 mg. For the parenteral route of administration,the dose usually should not exceed about 1 mg, preferably about 100 μg.

When used as vaccine agents, polynucleotides and polypeptides of theinvention can be used sequentially as part of a multistep immunizationprocess. For example, a mammal can be initially primed with a vaccinevector of the invention such as a pox virus, e.g., via the parenteralroute, and then boosted twice with the polypeptide encoded by thevaccine vector, e.g., via the mucosal route. In another example,liposomes associated with a polypeptide or derivative of the inventioncan also be used for priming, with boosting being carried out mucosallyusing a soluble polypeptide or derivative of the invention incombination with a mucosal adjuvant (e.g., LT).

A polypeptide derivative of the invention is also useful as a diagnosticreagent for detecting the presence of anti-Chlamydia antibodies, e.g.,in a blood sample. Such polypeptides are about 5 to about 80, preferablyabout 10 to about 50 amino acids in length and can be labeled orunlabeled, depending upon the diagnostic method. Diagnostic methodsinvolving such a reagent are described below.

Upon expression of a DNA molecule of the invention, a polypeptide orpolypeptide derivative is produced and can be purified using knownlaboratory techniques. For example, the polypeptide or polypeptidederivative can be produced as a fusion protein containing a fused tailthat facilitates purification. The fusion product can be used toimmunize a small mammal, e.g., a mouse or a rabbit, in order to raiseantibodies against the polypeptide or polypeptide derivative(monospecific antibodies). The eighth aspect of the invention thusprovides a monospecific antibody that binds to a polypeptide orpolypeptide derivative of the invention.

By “monospecific antibody” is meant an antibody that is capable ofreacting with a unique naturally-occurring Chlamydia polypeptide. Anantibody of the invention can be polyclonal or monoclonal. Monospecificantibodies can be recombinant, e.g., chimeric (e.g., constituted by avariable region of murine origin associated with a human constantregion), humanized (a human immunoglobulin constant backbone togetherwith hypervariable region of animal, e.g., murine, origin), and/orsingle chain. Both polyclonal and monospecific antibodies can also be inthe form of immunoglobulin fragments, e.g., F(ab)′2 or Fab fragments.The antibodies of the invention can be of any isotype, e.g., IgG or IgA,and polyclonal antibodies can be of a single isotype or can contain amixture of isotypes.

The antibodies of the invention, which are raised to a polypeptide orpolypeptide derivative of the invention, can be produced and identifiedusing standard immunological assays, e.g., Western blot analysis, dotblot assay, or ELISA (see, e.g., Coligan et al., Current Protocols inImmunology (1994) John Wiley & Sons, Inc., New York, N.Y.). Theantibodies can be used in diagnostic methods to detect the presence of aChlamydia antigen in a sample, such as a biological sample. Theantibodies can also be used in affinity chromatography methods forpurifying a polypeptide or polypeptide derivative of the invention. Asis discussed further below, such antibodies can be used in prophylacticand therapeutic passive immunization methods.

Accordingly, a ninth aspect of the invention provides (i) a reagent fordetecting the presence of Chlamydia in a biological sample that containsan antibody, polypeptide, or lo polypeptide derivative of the invention;and (ii) a diagnostic method for detecting the presence of Chlamydia ina biological sample, by contacting the biological sample with anantibody, a polypeptide, or a polypeptide derivative of the invention,such that an immune complex is formed, and by detecting such complex toindicate the presence of Chlamydia in the sample or the organism fromwhich the sample is derived.

Those skilled in the art will understand that the immune complex isformed between a component of the sample and the antibody, polypeptide,or polypeptide derivative, whichever is used, and that any unboundmaterial can be removed prior to detecting the complex. As can be easilyunderstood, a polypeptide reagent is useful for detecting the presenceof anti-Chlamydia antibodies in a sample, e.g., a blood sample, while anantibody of the invention can be used for screening a sample, such as agastric extract or biopsy, for the presence of Chlamydia polypeptides.

For use in diagnostic applications, the reagent (i.e., the antibody,polypeptide, or polypeptide derivative of the invention) can be in afree state or immobilized on a solid support, such as a tube, a bead, orany other conventional support used in the field. Immobilization can beachieved using direct or indirect means. Direct means include passiveadsorption (non-covalent binding) or covalent binding between thesupport and the reagent. By “indirect means” is meant that ananti-reagent compound that interacts with a reagent is first attached tothe solid support. For example, if a polypeptide reagent is used, anantibody that binds to it can serve as an anti-reagent, provided that itbinds to an epitope that is not involved in the recognition ofantibodies in biological samples. Indirect means can also employ aligand-receptor system, for example, a molecule such as a vitamin can begrafted onto the polypeptide reagent and the corresponding receptor canbe immobilized on the solid phase. This is illustrated by thebiotin-streptavidin system. Alternatively, indirect means can be used,e.g., by adding to the reagent a peptide tail, chemically or by geneticengineering, and immobilizing the grafted or fused product by passiveadsorption or covalent linkage of the peptide tail.

According to a tenth aspect of the invention, there is provided aprocess for purifying, from a biological sample, a polypeptide orpolypeptide derivative of the invention, which involves carrying outantibody-based affinity chromatography with the biological sample,wherein the antibody is a monospecific antibody of the invention.

For use in a purification process of the invention, the antibody can bepolyclonal or monospecific, and preferably is of the IgG type. PurifiedIgGs can be prepared from an antiserum using standard methods (see,e.g., Coligan et al., supra). Conventional chromatography supports, aswell as standard methods for grafting antibodies, are disclosed in,e.g., Antibodies: A Laboratory Manual, D. Lane, E. Harlow, Eds. (1988).

Briefly, a biological sample, such as an C. pneumoniae extract,preferably in a buffer solution, is applied to a chromatographymaterial, preferably equilibrated with the buffer used to dilute thebiological sample so that the polypeptide or polypeptide derivative ofthe invention (i.e., the antigen) is allowed to adsorb onto thematerial. The chromatography material, such as a gel or a resin coupledto an antibody of the invention, can be in batch form or in a column.The unbound components are washed off and the antigen is then elutedwith an appropriate elution buffer, such as a glycine buffer or a buffercontaining a chaotropic agent, e.g., guanidine HCl, or high saltconcentration (e.g., 3 M MgCl₂). Eluted fractions are recovered and thepresence of the antigen is detected, e.g., by measuring the absorbanceat 280 nm.

An antibody of the invention can be screened for therapeutic efficacy asdescribed as follows. According to an eleventh aspect of the invention,there is provided: (i) a composition of matter containing a monospecificantibody of the invention, together with a diluent or carrier; (ii) apharmaceutical composition containing a therapeutically orprophylactically effective amount of a monospecific antibody of theinvention, and (iii) a method for treating or preventing a Chlamydia(e.g., C. trachomatis, C. psittaci, C. pneumoniae or C. pecorum)infection, by administering a therapeutic or prophylactic amount of amonospecific antibody of the invention to an individual in need.Additionally, the eleventh aspect of the invention encompasses the useof a monospecific antibody of the invention in the preparation of amedicament for treating or preventing Chlamydia infection.

To this end, the monospecific antibody can be polyclonal or monoclonal,preferably of the IgA isotype (predominantly). In passive immunization,the antibody can be administered to a mucosal surface of a mammal, e.g.,the gastric mucosa, e.g., orally or intragastrically, advantageously, inthe presence of a bicarbonate buffer. Alternatively, systemicadministration, not requiring a bicarbonate buffer, can be carried out.A monospecific antibody of the invention can be administered as a singleactive component or as a mixture with at least one monospecific antibodyspecific for a different Chlamydia polypeptide. The amount of antibodyand the particular regimen used can be readily determined by one skilledin the art. For example, daily administration of about 100 to 1,000 mgof antibodies over one week, or three doses per day of about 100 to1,000 mg of antibodies over two or three days, can be an effectiveregimens for most purposes.

Therapeutic or prophylactic efficacy can be evaluated using standardmethods in the art, e.g., by measuring induction of a mucosal immuneresponse or induction of protective and/or therapeutic immunity, using,e.g., the C. pneumoniae mouse model. Those skilled in the art willrecognize that the C. pneumoniae strain of the model can be replacedwith another Chlamydia strain. For example, the efficacy of DNAmolecules and polypeptides from C. pneumoniae is preferably evaluated ina mouse model using an C. pneumoniae strain. Protection can bedetermined by comparing the degree of Chlamydia infection to that of acontrol group. Protection is shown when infection is reduced bycomparison to the control group. Such an evaluation can be made forpolynucleotides, vaccine vectors, polypeptides and derivatives thereof,as well as antibodies of the invention.

Adjuvants useful in any of the vaccine compositions described above areas follows.

Adjuvants for parenteral administration include aluminum compounds, suchas aluminum hydroxide, aluminum phosphate, and aluminum hydroxyphosphate. The antigen can be precipitated with, or adsorbed onto, thealuminum compound according to standard protocols. Other adjuvants, suchas RIBI (ImmunoChem, Hamilton, Mont.), can be used in parenteraladministration.

Adjuvants for mucosal administration include bacterial toxins, e.g., thecholera toxin (CT), the E. coli heat-labile toxin (LT), the Clostridiumdifficile toxin A and the pertussis toxin (PT), or combinations,subunits, toxoids, or mutants thereof For example, a purifiedpreparation of native cholera toxin subunit B (CTB) can be of use.Fragments, homologs, derivatives, and fusions to any of these toxins arealso suitable, provided that they retain adjuvant activity. Preferably,a mutant having reduced toxicity is used. Suitable mutants aredescribed, e.g., in WO 95/17211 (Arg-7-Lys CT mutant), WO 96/6627(Arg-192-Gly LT mutant), and WO 95/34323 (Arg-9-Lys and Glu-129-Gly PTmutant). Additional LT mutants that can be used in the methods andcompositions of the invention include, e.g., Ser-63-Lys, Ala-69-Gly,Glu-110-Asp, and Glu-112-Asp mutants. Other adjuvants, such as abacterial monophosphoryl lipid A (MPLA) of, e.g., E. coli, Salmonellaminnesota, Salmonella typhimurium, or Shigella flexneri; saponins, orpolylactide glycolide (PLGA) microspheres, can also be used in mucosaladministration.

Adjuvants usefuil for both mucosal and parenteral administrationsinclude polyphosphazene (WO 95/2415), DC-chol (3 b-(N-(N′,N′-dimethylaminomethane)-carbamoyl) cholesterol (U.S. Pat. No. 5,283,185 and WO96/14831) and QS-21 (WO 88/9336).

Any pharmaceutical composition of the invention, containing apolynucleotide, a polypeptide, a polypeptide derivative, or an antibodyof the invention, can be manufactured in a conventional manner. Inparticular, it can be formulated with a pharmaceutically acceptablediluent or carrier, e.g., water or a saline solution such as phosphatebuffer saline. In general, a diluent or carrier can be selected on thebasis of the mode and route of administration, and standardpharmaceutical practice. Suitable pharmaceutical carriers or diluents,as well as pharmaceutical necessities for their use in pharmaceuticalformulations, are described in Remington's Pharmaceutical Sciences, astandard reference text in this field and in the USP/NF.

The invention also includes methods in which Chlamydia infection, aretreated by oral administration of a Chlamydia polypeptide of theinvention and a mucosal adjuvant, in combination with an antibiotic, anantacid, sucralfate, or a combination thereof. Examples of suchcompounds that can be administered with the vaccine antigen and theadjuvant are antibiotics, including, e.g., macrolides, tetracyclines,and derivatives thereof (specific examples of antibiotics that can beused include azithromycin or doxicyclin or immunomodulators such ascytokines or steroids. In addition, compounds containing more than oneof the above-listed components coupled together, can be used. Theinvention also includes compositions for carrying out these methods,i.e., compositions containing a Chlamydia antigen (or antigens) of theinvention, an adjuvant, and one or more of the above-listed compounds,in a pharmaceutically acceptable carrier or diluent.

Amounts of the above-listed compounds used in the methods andcompositions of the invention can readily be determined by one skilledin the art. In addition, one skilled in the art can readily designtreatment/immunization schedules. For example, the non-vaccinecomponents can be administered on days 1-14, and the vaccineantigen+adjuvant can be administered on days 7, 14, 21, and 28.

The above disclosure generally describes the present invention. A morecomplete understanding can be obtained by reference to the followingspecific examples. These examples are described solely for purposes ofillustration and are not intended to limit the scope of the invention.Changes in form and substitution of equivalents are contemplated ascircumstances may suggest or render expedient. Although specific termshave been employed herein, such terms are intended in a descriptivesense and not for purposes of limitation. Polypeptides having a sequencehomologous to one of the sequences shown in SEQ ID NOS: 1 and 2, includenaturally-occurring allelic variants, as well as mutants or any othernon-naturally occurring variants that are analogous in terms ofantigenicity, to a polypeptide.

As is known in the art, an allelic variant is an alternate form of apolypeptide that is characterized as having a substitution, deletion, oraddition of one or more amino acids that does not alter the biologicalfunction of the polypeptide. By “biological function” is meant thefunction of the polypeptide in the cells in which it naturally occurs,even if the function is not necessary for the growth or survival of thecells. For example, the biological function of a porin is to allow theentry into cells of compounds present in the extracellular medium. Thebiological function is distinct from the antigenic function. Apolypeptide can have more than one biological function.

Allelic variants are very common in nature. For example, a bacterialspecies, e.g., C. pneumoniae, is usually represented by a variety ofstrains that differ from each other by minor allelic variations. Indeed,a polypeptide that fulfills the same biological function in differentstrains can have an amino acid sequence that is not identical in each ofthe strains. Such an allelic variation may be equally reflected at thepolynucleotide level.

Support for the use of allelic variants of polypeptide antigens comesfrom, e.g., studies of the Chlamydial MOMP antigen. The amino acidsequence of the MOMP varies from strain to strain, yet cross-strainantibody binding plus neutralization of infectivity occurs, indicatingthat the MOMP, when used as an immunogen, is tolerant of amino acidvariations.

Polynucleotides, e.g., DNA molecules, encoding allelic variants caneasily be retrieved by polymerase chain reaction (PCR) amplification ofgenomic bacterial DNA extracted by conventional methods. This involvesthe use of synthetic oligonucleotide primers matching upstream anddownstream of the 5′ and 3′ ends of the encoding domain. Suitableprimers can be designed according to the nucleotide sequence informationprovided in SEQ ID NOS: 1 and 2. Typically, a primer can consist of 10to 40, preferably 15 to 25 nucleotides. It may be also advantageous toselect primers containing C and G nucleotides in a proportion sufficientto ensure efficient hybridization; e.g., an amount of C and Gnucleotides of at least 40%, preferably 50% of the total nucleotideamount.

Useful homologs that do not naturally occur can be designed using knownmethods for identifying regions of an antigen that are likely to betolerant of amino acid sequence changes and/or deletions. For example,sequences of the antigen from different species can be compared toidentify conserved sequences.

Polypeptide derivatives that are encoded by polynucleotides of theinvention include, e.g., fragments, polypeptides having large internaldeletions derived from full-length polypeptides, and fusion proteins.

Polypeptide fragments of the invention can be derived from a polypeptidehaving a sequence homologous to any of the sequences shown in SEQ ID NO:1, to the extent that the fragments retain the substantial antigenicityof the parent polypeptide (specific antigenicity). Polypeptidederivatives can also be constructed by large internal deletions thatremove a substantial part of the parent polypeptide, while retainingspecific antigenicity. Generally, polypeptide derivatives should beabout at least 12 amino acids in length to maintain antigenicity.Advantageously, they can be at least 20 amino acids, preferably at least50 amino acids, more preferably at least 75 amino acids, and mostpreferably at least 100 amino acids in length. Useful polypeptidederivatives, e.g., polypeptide fragments, can be designed usingcomputer-assisted analysis of amino acid sequences in order to identifysites in protein antigens having potential as surface-exposed, antigenicregions. See e.g., Hughes et al., Infect. Immun. 60: 3497 (1992).

Polypeptide fragments and polypeptides having large internal deletionscan be used for revealing epitopes that are otherwise masked in theparent polypeptide and that may be of importance for inducing aprotective T cell-dependent immune response. Deletions can also removeimmunodominant regions of high variability among strains.

It is an accepted practice in the field of immunology to use fragmentsand variants of protein immunogens as vaccines, as all that is requiredto induce an immune response to a protein is a small (e.g., 8 to 10amino acid) immunogenic region of the protein. This has been done for anumber of vaccines against pathogens other than Chlamydia. For example,short synthetic peptides corresponding to surface-exposed antigens ofpathogens such as murine mammary tumor virus, peptide containing 11amino acids; (see e.g., Dion et al., Virology 179: 474-477 (1990))Semliki Forest virus, peptide containing 16 amino acids (see e.g.,Snijders et al., J. Gen. Virol. 72: 557-565 (1991)), and canineparvovirus, 2 overlapping peptides, each containing 15 amino acids (seee.g., Langeveld et al. Vaccine 12: 1473-1480 (1994)), have been shown tobe effective vaccine antigens against their respective pathogens.

Polynucleotides encoding polypeptide fragments and polypeptides havinglarge internal deletions can be constructed using standard methods, forexample, by PCR, including inverse PCR, by restriction enzyme treatmentof the cloned DNA molecules, or. by the method of Kunkel et al. (Proc.Natl. Acad. Sci. USA 82:448 (1985)) using biological material availableat Stratagene.

A polypeptide derivative can also be produced as a fusion polypeptidethat contains a polypeptide or a polypeptide derivative of the inventionfused, e.g., at the N- or C-terminal end, to any other polypeptide(hereinafter referred to as a peptide tail). Such a product can beeasily obtained by translation of a genetic fusion, i.e., a hybrid gene.Vectors for expressing fusion polypeptides are commercially available,such as the pMal-c2 or pMal-p2 systems of New England Biolabs, in whichthe peptide tail is a maltose binding protein, theglutathione-S-transferase system of Pharmacia, or the His-Tag systemavailable from Novagen. These and other expression systems provideconvenient means for further purification of polypeptides andderivatives of the invention.

Another particular example of fusion polypeptides included in inventionincludes a polypeptide or polypeptide derivative of the invention fusedto a polypeptide having adjuvant activity, such as, e.g., subunit B ofeither cholera toxin or E. coli heat-labile toxin. Several possibilitiesare can be used for achieving fusion. First, the polypeptide of theinvention can be fused to the N-, or preferably, to the C-terminal endof the polypeptide having adjuvant activity. Second, a polypeptidefragment of the invention can be fused within the amino acid sequence ofthe polypeptide having adjuvant activity.

As stated above, the polynucleotides of the invention encode Chlamydiapolypeptides in precursor or mature form. They can also encode hybridprecursors containing heterologous signal peptides, which can matureinto polypeptides of the invention. By “heterologous signal peptide” ismeant a signal peptide that is not found in the naturally-occurringprecursor of a polypeptide of the invention.

A polynucleotide of the invention, having a homologous coding sequence,hybridizes, preferably under stringent conditions, to a polynucleotidehaving a sequence as shown in SEQ ID NOS: 1 or 2. Hybridizationprocedures are, described in e.g., Ausubel et al., Current Protocols inMolecular Biology, John Wiley & Sons Inc. (1994), Silhavy et al.Experiments With Genetic Fusions, Cold Spring Harbor Laboratory Press(1984); Davis et al., A Manual for Genetic Engineering: AdvancedBacterial Genetics, Cold Spring Harbor Laboratory Press (1980).Important parameters that can be considered for optimizing hybridizationconditions are reflected in a formula that allows calculation of acritical value, the melting temperature above which two complementaryDNA strands separate from each other. Casey and Davidson, Nucl. AcidRes. 4: 1539 (1977). This formula is as follows: Tm=81.5+0.41×(%G+C)+16.6 log (cation ion concentration)−0.63×(% formamide)−600/basenumber. Under appropriate stringency conditions, hybridizationtemperature (Th) is approximately 20-40° C., 20-25° C., or, preferably30-40° C. below the calculated Tm. Those skilled in the art willunderstand that optimal temperature and salt conditions can be readilydetermined empirically in preliminary experiments using conventionalprocedures.

For example, stringent conditions can be achieved, both forpre-hybridizing and hybridizing incubations, (i) within 4-16 hours at42° C., in 6×SSC containing 50% formamide or (ii) within 4-16 hours at65° C. in an aqueous 6×SSC solution (1 M NaCl, 0.1 M sodium citrate (pH7.0)). Typically, hybridization experiments are performed at atemperature from 60 to 68° C., e.g., 65° C. At such a temperature,stringent hybridization conditions can be achieved in 6×SSC, preferablyin 2×SSC or 1×SSC, more preferably in 0.5×SSc, 0.3×SSC or 0.1×SSC (inthe absence of formamide). 1×SSC contains 0.15 M NaCl and 0.015 M sodiumcitrate.

For polynucleotides containing 30 to 600 nucleotides, the above formulais used and then is corrected by subtracting (600/polynucleotide size inbase pairs). Stringency conditions are defined by a Th that is 5 to 10°C. below Tm.

Hybridization conditions with oligonucleotides shorter than 20-30 basesdo not exactly follow the rules set forth above. In such cases, theformula for calculating the Tm is as follows: Tm=4×(G+C)+2(A+T). Forexample, an 18 nucleotide fragment of 50% G+C would have an approximateTm of 54° C.

A polynucleotide molecule of the invention, containing RNA, DNA, ormodifications or combinations thereof, can have various applications.For example, a DNA molecule can be used (i) in a process for producingthe dncoded polypeptide in a recombinant host system, (ii) in theconstruction of vaccine vectors such as poxviruses, which are furtherused in methods and compositions for preventing and/or treatingChlamydia infection, (iii) as a vaccine agent (as well as an RNAmolecule), in a naked form or formulated with a delivery vehicle and,(iv) in the construction of attenuated Chlamydia strains that canover-express a polynucleotide of the invention or express it in anon-toxic, mutated form.

According to a second aspect of the invention, there is thereforeprovided (i) an expression cassette containing a DNA molecule of theinvention placed under the control of the elements required forexpression, in particular under the control of an appropriate promoter;(ii) an expression vector containing an expression cassette of theinvention; (iii) a procaryotic or eucaryotic cell transformed ortransfected with an expression cassette and/or vector of the invention,as well as (iv) a process for producing a polypeptide or polypeptidederivative encoded by a polynucleotide of the invention, which involvesculturing a procaryotic or eucaryotic cell transformed or transfectedwith an expression cassette and/or vector of the invention, underconditions that allow expression of the DNA molecule of the inventionand, recovering the encoded polypeptide or polypeptide derivative fromthe cell culture.

A recombinant expression system can be selected from procaryotic andeucaryotic hosts. Eucaryotic hosts include yeast cells (e.g.,Saccharomyces cerevisiae or Pichia pastoris), mammalian cells (e.g., COS1, NIH3T3, or JEG3 cells), arthropods cells (e.g., Spodoptera frugiperda(SF9) cells), and plant cells. Preferably, a procaryotic host such as E.coli is used. Bacterial and eucaryotic cells are available from a numberof different sources to those skilled in the art, e.g., the AmericanType Culture Collection (ATCC; Rockville, Md.).

The choice of the expression system depends on the features desired forthe expressed polypeptide. For example, it may be useful to produce apolypeptide of the invention in a particular lipidated form or any otherform.

The choice of the expression cassette will depend on the host systemselected as well as the features desired for the expressed polypeptide.Typically, an expression cassette includes a promoter that is functionalin the selected host system and can be constitutive or inducible; aribosome binding site; a start codon (ATG) if necessary, a regionencoding a signal peptide, e.g., a lipidation signal peptide; a DNAmolecule of the invention; a stop codon; and optionally a 3′ terminalregion (translation and/or transcription terminator). The signalpeptide-encoding region is adjacent to the polynucleotide of theinvention and placed in proper reading frame. The signalpeptide-encoding region can be homologous or heterologous to the DNAmolecule encoding the mature polypeptide and can be specific to thesecretion apparatus of the host used for expression. The open readingframe constituted by the DNA molecule of the invention, solely ortogether with the signal peptide, is placed under the control of thepromoter so that transcription and translation occur in the host system.Promoters, signal peptide encoding loregions are widely known andavailable to those skilled in the art and includes, for example, thepromoter of Salmonella typhimuriun (and derivatives) that is inducibleby arabinose (promoter araB) and is functional in Gram-negative bacteriasuch as E. coli (as described in U.S. Pat. No. 5,028,530 and in Cagnonet al., Protein Engineering 4: 843 (1991); the promoter of the gene ofbacteriophage T7 encoding RNA polymerase, that is functional in a numberof E. coli strains expressing T7 polymerase (described in U.S. Pat. No.4,952,496); OspA lipidation signal peptide; and RlpB lipidation signalpeptide. See Takase et al., J. Bact. 169: 5692 (1987).

The expression cassette is typically part of an expression vector, whichis selected for its ability to replicate in the chosen expressionsystem. Expression vectors (e.g., plasmids or viral vectors) can bechosen from those described in Pouwels et al. (Cloning Vectors: ALaboratory Manual 1985, Suppl. 1987). They can be purchased from variouscommercial sources.

Methods for transforming/transfecting host cells with expression vectorswill depend on the host system selected as described in Ausubel et al.,Current Protocols in Molecular Biology, John Wiley & Sons Inc. (1994)).

Upon expression, a recombinant polypeptide of the invention (or apolypeptide derivative) is produced and remains in the intracellularcompartment, is secreted/excreted in the extracellular medium or in theperiplasmic space, or is embedded in the cellular membrane. Thepolypeptide can then be recovered in a substantially purified form fromthe cell extract or from the supematant after centriftigation of therecombinant cell culture. Typically, the recombinant polypeptide can bepurified by antibody-based affinity purification or by any other methodthat can be readily adapted by a person skilled in the art, such as bygenetic fuision to a small affinity binding domain. Antibody-basedaffinity purification methods are also available for purifying apolypeptide of the invention extracted from a Chlamydia strain.Antibodies useful for purifying by immunoaffinity the polypeptides ofthe invention can be obtained as described below.

A polynucleotide of the invention can also be usefuil in the vaccinefield, e.g., for achieving DNA vaccination. There are two majorpossibilities, either using a viral or bacterial host as gene deliveryvehicle (live vaccine vector) or administering the gene in a free form,e.g., inserted into a plasmid. Therapeutic or prophylactic efficacy of apolynucleotide of the invention can be evaluated as described below.

Accordingly, in a third aspect of the invention, there is provided (i) avaccine vector such as a poxvirus, containing a DNA molecule of theinvention, placed under the control of elements required for expression;(ii) a composition of matter containing a vaccine vector of theinvention, together with a diluent or carrier; particularly, (iii) apharmaceutical composition containing a therapeutically orprophylactically effective amount of a vaccine vector of the invention;(iv) a method for inducing an immune response against Chlamydia in amammal (e.g., a human; altematively, the method can be used inveterinary applications for treating or preventing Chlamydia infectionof animals, e.g., cats or birds), which involves administering to themammal an immunogenically effective amount of a vaccine vector of theinvention to elicit an immune response, e.g., a protective ortherapeutic immune response to Chlamydia; and particularly, (v) a methodfor preventing and/or treating a Chlamydia (e.g., C. trachomatis, C.psittaci, C. pneumoniae, C. pecorum) infection, which involvesadministering a prophylactic or therapeutic amount of a vaccine vectorof the invention to an individual in need. Additionally, the thirdaspect of the invention encompasses the use of a vaccine vector of theinvention in the preparation of a medicament for preventing and/ortreating Chlamydia infection.

A vaccine vector of the invention can express one or severalpolypeptides or derivatives of the invention, as well as at least oneadditional Chlamydia antigen, fragment, homolog, mutant, or derivativethereof. In addition, it can express a cytokine, such as interleukin-2(IL-2) or interleukin-12 (IL-12), which enhances the immune response(adjuvant effect). Thus, a vaccine vector can include an additional DNAsequence encoding, e.g., a chlamydial antigen, or a cytokine, placedunder the control of elements required for expression in a mammaliancell.

Alternatively, a composition of the invention can include severalvaccine vectors, each of them being capable of expressing a polypeptideor derivative of the invention. A composition can also contain a vaccinevector capable of expressing an additional Chlamydia antigen, or asubunit, fragment, homolog, mutant, or derivative thereof, or a cytokinesuch as IL-2 or IL-12.

In vaccination methods for treating or preventing infection in a mammal,a vaccine vector of the invention can be administered by anyconventional route in use in the vaccine field, particularly, to amucosal (e.g., ocular, intranasal, oral, gastric, pulmonary, intestinal,rectal, vaginal, or urinary tract) surface or via the parenteral (e.g.,subcutaneous, intradermal, intramuscular, intravenous, orintraperitoneal) route. Preferred routes depend upon the choice of thevaccine vector. The administration can be achieved in a single dose orrepeated at intervals. The appropriate dosage depends on variousparameters understood by skilled artisans such as the vaccine vectoritself, the route of administration or the condition of the mammal to bevaccinated (weight, age and the like).

Live vaccine vectors available in the art include viral vectors such asadenoviruses and poxviruses as well as bacterial vectors, e.g.,Shigella, Salmonella, Vibrio cholerae, Lactobacillus, Bacille bilié deCalmette-Guérin (BCG), and Streptococcus.

An example of an adenovirus vector, as well as a method for constructingan adenovirus vector capable of expressing a DNA molecule of theinvention, are described in U.S. Pat. No. 4,920,209. Poxvirus vectorsthat can be used include, e.g., vaccinia and canary pox virus, describedin U.S. Pat. No. 4,722,848 and U.S. Pat. No. 5,364,773, respectively(also see, e.g., Tartaglia et al., Virology (1992) 188:217) for adescription of a vaccinia virus vector; and Taylor et al, Vaccine (1995)13:539 for a reference of a canary pox). Poxvirus vectors capable ofexpressing a polynucleotide of the invention can be obtained byhomologous recombination as described in Kieny et al., Nature (1984)312:163 so that the polynucleotide of the invention is inserted in theviral genome under appropriate conditions for expression in mammaliancells. Generally, the dose of vaccine viral vector, for therapeutic orprophylactic use, can be of from about 1×10⁴ to about 1×10¹¹,advantageously from about 1×10⁷ to about 1×10¹⁰, preferably of fromabout 1×10⁷ to about 1×10⁹ plaque-forming units per kilogram.Preferably, viral vectors are administered parenterally; for example, in3 doses, 4 weeks apart. Those skilled in the art recognize that it ispreferable to avoid adding a chemical adjuvant to a compositioncontaining a viral vector of the invention and thereby minimizing theimmune response to the viral vector itself.

Non-toxicogenic Vibrio cholerae mutant strains that are useful as a liveoral vaccine are described in Mekalanos et al., Nature (1983) 306:551and U.S. Pat. No. 4,882,278 (strain in which a substantial amount of thecoding sequence of each of the two ctxA alleles has been deleted so thatno functional cholerae toxin is produced); WO 92/11354 (strain in whichthe irgA locus is inactivated by mutation; this mutation can be combinedin a single strain with ctxA mutations); and WO 94/1533 (deletion mutantlacking functional ctxA and attRS1 DNA sequences). These strains can begenetically engineered to express heterologous antigens, as described inWO 94/19482. An effective vaccine dose of a Vibrio cholerae straincapable of expressing a polypeptide or polypeptide derivative encoded bya DNA molecule of the invention can contain, e.g., about 1×10⁵ to about1×10⁹, preferably about 1×10⁶ to about 1×10⁸ viable bacteria in anappropriate volume for the selected route of administration. Preferredroutes of administration include all mucosal routes; most preferably,these vectors are administered intranasally or orally.

Attenuated Salmonella typhimurium strains, genetically engineered forrecombinant expression of heterologous antigens or not, and their use asoral vaccines are described in Nakayama et al. (Bio/Technology (1988)6:693) and WO 92/11361. Preferred routes of administration include allmucosal routes; most preferably, these vectors are administeredintranasally or orally.

Others bacterial strains useful as vaccine vectors are described in Highet al., EMBO (1992) 11:1991 and Sizemore et al., Science (1995) 270:299(Shigella flexneri); Medaglini et al., Proc. Natl. Acad. Sci. USA (1995)92:6868 (Streptococcus gordonii); and Flynn J. L., Cell. Mol. Biol.(1994) 40 (suppl. I):31, WO 88/6626, WO 90/0594, WO 91/13157, WO92/1796, and WO 92/21376 (Bacille Calmette Guerin).

In bacterial vectors, polynucleotide of the invention can be insertedinto the bacterial genome or can remain in a free state, carried on aplasmid.

An adjuvant can also be added to a composition containing a vaccinebacterial vector. A number of adjuvants are known to those skilled inthe art. Preferred adjuvants can be selected from the list providedbelow.

According to a fourth aspect of the invention, there is also provided(i) a composition of matter containing a polynucleotide of theinvention, together with a diluent or carrier; (ii) a pharmaceuticalcomposition containing a therapeutically or prophylactically effectiveamount of a polynucleotide of the invention; (iii) a method for inducingan immune response against Chlamydia, in a mammal, by administering tothe mammal, an immunogenically effective amount of a polynucleotide ofthe invention to elicit an immune response, e.g., a protective immuneresponse to Chlamydia; and particularly, (iv) a method for preventingand/or treating a Chlamydia (e.g., C. trachomatis, C. psittaci, C.pneumoniae, or C. pecorum) infection, by administering a prophylactic ortherapeutic amount of a polynucleotide of the invention to an individualin need. Additionally, the fourth aspect of the invention encompassesthe use of a polynucleotide of the invention in the preparation of amedicament for preventing and/or treating Chlamydia infection. Thefourth aspect of the invention preferably includes the use of a DNAmolecule placed under conditions for expression in a mammalian cell,e.g., in a plasmid that is unable to replicate in mammalian cells and tosubstantially integrate in a mammalian genome.

Polynucleotides (DNA or RNA) of the invention can also be administeredas such to a mammal for vaccine, e.g., therapeutic or prophylactic,purpose. When a DNA molecule of the invention is used, it can be in theform of a plasmid that is unable to replicate in a mammalian cell andunable to integrate in the mammalian genome. Typically, a DNA moleculeis placed under the control of a promoter suitable for expression in amammalian cell. The promoter can function ubiquitously ortissue-specifically. Examples of non-tissue specific promoters includethe early Cytomegalovirus (CMV) promoter (described in U.S. Pat. No.4,168,062) and the Rous Sarcoma Virus promoter (described in Norton &Coffin, Molec. Cell Biol. 5:281 (1985)). The desmin promoter (Li et al.,Gene 78: 243 (1989); Li & Paulin, J. Biol, Chem. 266: 6562 (1991); andLi & Paulin, J. Biol. Chem. 268: 10403 (1993)) is tissue-specific anddrives expression in muscle cells. More generally, useful vectors aredescribed, i.a., WO 94/21797 and Hartikka et al., Human Gene Therapy 7:1205 (1996).

For DNA/RNA vaccination, the polynucleotide of the invention can encodea precursor or a mature form. When it encodes a precursor form, theprecursor form can be homologous or heterologous. In the latter case, aeucaryotic leader sequence can be used, such as the leader sequence ofthe tissue-type plasminogen factor (tPA).

A composition of the invention can contain one or severalpolynucleotides of the invention. It can also contain at least oneadditional polynucleotide encoding another Chlamydia antigen such asurease subunit A, B, or both; or a fragment, derivative, mutant, oranalog thereof. A polynucleotide encoding a cytokine, such asinterleukin-2 (IL-2) or interleukin-12 (IL-12), can also be added to thecomposition so that the immune response is enhanced. These additionalpolynucleotides are placed under appropriate control-for expression.Advantageously, DNA molecules of the invention and/or additional DNAmolecules to be included in the same composition, can be carried in thesame plasmid.

Standard techniques of molecular biology for preparing and purifyingpolynucleotides can be used in the preparation of polynucleotidetherapeutics of the invention. For use as a vaccine, a polynucleotide ofthe invention can be formulated according to various methods.

First, a polynucleotide can be used in a naked form, free of anydelivery vehicles, such as anionic liposomes, cationic lipids,microparticles, e.g., gold microparticles, precipitating agents, e.g.,calcium phosphate, or any other transfection-facilitating agent. In thiscase, the polynucleotide can be simply diluted in a physiologicallyacceptable solution, such as sterile saline or sterile buffered saline,with or without a carrier. When present, the carrier preferably isisotonic, hypotonic, or weakly hypertonic, and has a relatively lowionic strength, such as provided by a sucrose solution, e.g., a solutioncontaining 20% sucrose.

Alternatively, a polynucleotide can be associated with agents thatassist in cellular uptake. It can be, i.a., (i) complemented with achemical agent that modifies the cellular permeability, such asbupivacaine (see, e.g., WO 94/16737), (ii) encapsulated into liposomes,or (iii) associated with cationic lipids or silica, gold, or tungstenmicroparticles.

Anionic and neutral liposomes are well known in the art (see, e.g.,Liposomes: A Practical Approach, RPC New Ed, IRL press (1990), for adetailed description of methods for making liposomes) and are useful fordelivering a large range of products, including polynucleotides.

Cationic lipids are also known in the art and are commonly used for genedelivery. Such lipids include Lipofectin™ also known as DOTMA(N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride), DOTAP(1,2-bis(oleyloxy)-3-(trimethylammonio)propane), DDAB(dimethyldioctadecylammonium bromide), DOGS (dioctadecylamidologlycylspermine) and cholesterol derivatives such as DC-Chol (3beta-(N-(N′,N′-dimethyl aminomethane)-carbamoyl) cholesterol). Adescription of these cationic lipids can be found in EP 187,702, WO90/11092, U.S. Pat. No. 5,283,185, WO 91/15501, WO 95/26356, and U.S.Pat. No. 5,527,928. Cationic lipids for gene delivery are preferablyused in association with a neutral lipid such as DOPE (dioleylphosphatidylethanolamine), as, for example, described in WO 90/11092.

Other transfection-facilitating compounds can be added to a formulationcontaining cationic liposomes. A number of them are described in, e.g.,WO 93/18759, WO 93/19768, WO 94/25608, and WO 95/2397. They include,i.a., spermine derivatives useful for facilitating the transport of DNAthrough the nuclear membrane (see, for example, WO 93/18759) andmembrane-permeabilizing compounds such as GALA, Gramicidine S, andcationic bile salts (see, for example, WO 93/19768).

Gold or tungsten microparticles can also be used for gene delivery, asdescribed in WO 91/359, WO 93/17706, and Tang et al. (Nature 356: 152(1992)). In this case, the microparticle-coated polynucleotides can beinjected via intradeimal or intra-epidermal routes using a needlelessinjection device (“gene gun”), such as those described in U.S. Pat. No.4,945,050, U.S. Pat. No. 5,015,580, and WO 94/24263.

The amount of DNA to be used in a vaccine recipient depends, e.g., onthe strength of the promoter used in the DNA construct, theimmunogenicity of the expressed gene product, the condition of themammal intended for administration (e.g., the weight, age, and generalhealth of the mammal), the mode of administration, and the type offormulation. In general, a therapeutically or prophylactically effectivedose from about 1 μg to about 1 mg, preferably, from about 10 μg toabout 800 μg and, more preferably, from about 25 μg to about 250 μg, canbe administered to human adults. The administration can be achieved in asingle dose or repeated at intervals.

The route of administration can be any conventional route used in thevaccine field. As general guidance, a polynucleotide of the inventioncan be administered via a mucosal surface, e.g., an ocular, intranasal,pulmonary, oral, intestinal, rectal, vaginal, and urinary tract surface;or via a parenteral route, e.g., by an intravenous, subcutaneous,intraperitoneal, intradermal, intraepidermal, or intramuscular route.The choice of the administration route will depend on, e.g., theformulation that is selected. A polynucleotide formulated in associationwith bupivacaine is advantageously administered into muscles. When aneutral or anionic liposome or a cationic lipid, such as DOTMA orDC-Chol, is used, the formulation can be advantageously injected viaintravenous, intranasal (aerosolization), intramuscular, intradermal,and subcutaneous routes. A polynucleotide in a naked form canadvantageously be administered via the intramuscular, intradermal, orsub-cutaneous routes.

Although not absolutely required, such a composition can also contain anadjuvant. If so, a systemic adjuvant that does not require concomitantadministration in order to exhibit an adjuvant effect is preferable suchas, e.g., QS21, which is described in U.S. Pat. No. 5,057,546.

The sequence information provided in the present application enables thedesign of specific nucleotide probes and primers that can be useful indiagnosis. Accordingly, in a fifth aspect of the invention, there isprovided a nucleotide probe or primer having a sequence found in orderived by degeneracy of the genetic code from a sequence shown in SEQID NOS: 1 or 2.

The term “probe” as used in the present application refers to DNA(preferably single stranded) or RNA molecules (or modifications orcombinations thereof) that hybridize under the stringent conditions, asdefined above, to nucleic acid molecules having sequences homologous tothose shown in SEQ ID NOS: 1 and 2, or to a complementary or anti-sensesequence. Generally, probes are significantly shorter than full-lengthsequences shown in SEQ ID NOS: 1 and 2; for example, they can containfrom about 5 to about 100, preferably from about 10 to about 80nucleotides. In particular, probes have sequences that are at least 75%,preferably at least 85%, more preferably 95% homologous to a portion ofa sequence as shown in SEQ ID NOS: 1 and 2 or that are complementary tosuch sequences. Probes can contain modified bases such as inosine,methyl-5-deoxycytidine, deoxyuridine, dimethylamino-5-deoxyuridine, ordiamino-2, 6-purine. Sugar or phosphate residues can also be modified orsubstituted. For example, a deoxyribose residue can be replaced by apolyamide (Nielsen et al., Science (1991) 254:1497) and phosphateresidues can be replaced by ester groups such as diphosphate, alkyl,arylphosphonate and phosphorothioate esters. In addition, the2′-hydroxyl group on ribonucleotides can be modified by including, e.g.,alkyl groups.

Probes of the invention can.be used in diagnostic tests, as capture ordetection probes. Such capture probes can be conventionally immobilizedon a solid support, directly or indirectly, by covalent means or bypassive adsorption. A detection probe can be labelled by a detectionmarker selected from radioactive isotopes; enzymes such as peroxidase,alkaline phosphatase, and enzymes able to hydrolyze a chromogenic,fluorogenic, or luminescent substrate; compounds that are chromogenic,fluorogenic, or luminescent; nucleotide base analogs; and biotin.

Probes of the invention can be used in any conventional hybridizationtechnique, such as dot blot (Maniatis et al., Molecular Cloning: ALaboratory Manual (1982) Cold Spring Harbor Laboratory Press, ColdSpring Harbor, N.Y.), Southern blot (Southern, J. Mol. Biol. (1975)98:503), northern blot (identical to Southern blot to the exception thatRNA is used as a target), or the sandwich technique (Dunn et al., Cell12: 23 (1977)). The latter technique involves the use of a specificcapture probe and/or a specific detection probe with nucleotidesequences that at least partially differ from each other.

A primer is usually a probe of about 10 to about 40 nucleotides that isused to initiate enzymatic polymerization of DNA in an amplificationprocess (e.g., PCR), in an elongation process, or in a reversetranscription method. In a diagnostic method involving PCR, primers. canbe labelled.

Thus, the invention also encompasses (i) a reagent containing a probe ofthe invention for detecting and/or identifying the presence of Chlamydiain a biological material; (ii) a method for detecting and/or identifyingthe presence of Chlamydia in a biological material, in which (a) asample is recovered or derived from the biological material, (b) DNA orRNA is extracted from the material and denatured, and (c) exposed to aprobe of the invention, for example, a capture, detection probe or both,under stringent hybridization conditions, such that hybridization isdetected; and (iii) a method for detecting and/or identifying thepresence of Chlamydia in a biological material, in which (a) a sample isrecovered or derived from the biological material, (b) DNA is extractedtherefrom, (c) the extracted DNA is primed with at least one, andpreferably two, primers of the invention and amplified by polymerasechain reaction, and (d) the amplified DNA fragment is produced.

As previously mentioned, polypeptides that can be produced uponexpression of the newly identified open reading frames are usefulvaccine agents.

Therefore, a sixth aspect of the invention features a substantiallypurified polypeptide or polypeptide derivative having an amino acidsequence encoded by a polynucleotide of the invention.

A “substantially purified polypeptide” is defined as a polypeptide thatis separated from the environment in which it naturally occurs and/orthat is free of the majority of the polypeptides that are present in theenvironment in which it was synthesized. For example, a substantiallypurified polypeptide is free from cytoplasmic polypeptides. Thoseskilled in the art will understand that the polypeptides of theinvention can be purified from a natural source, i.e., a Chlamydiastrain, or can be produced by recombinant means.

Homologous polypeptides or polypeptide derivatives encoded bypolynucleotides of the invention can be screened for specificantigenicity by testing cross-reactivity with an antiserum raisedagainst the polypeptide of reference having an amino acid sequence asshown in SEQ ID NO: 2. Briefly, a monospecific hyperimmune antiserum canbe raised against a purified reference polypeptide as such or as afusion polypeptide, for example, an expression product of MBP, GST, orHis-tag systems or a synthetic peptide predicted to be antigenic. Thehomologous polypeptide or derivative screened for specific antigenicitycan be produced as such or as a fusion polypeptide. In this latter caseand if the antiserum is also raised against a fusion polypeptide, twodifferent fusion systems are employed. Specific antigenicity can bedetermined according to a number of methods, including Western blot(Towbin et al., Proc. Natl. Acad. Sci. USA 76: 4350 (1979)), dot blot,and ELISA, as described below.

In a Western blot assay, the product to be screened, either as apurified preparation or a total E. coli extract, is submitted toSDS-Page electrophoresis as described by Laemmli (Nature 227: 680(1970)). After transfer to a nitrocellulose membrane, the material isfurther incubated with the monospecific hyperimmune antiserum diluted inthe range of dilutions from about 1:5 to about 1:5000, preferably fromabout 1:100 to about 1:500. Specific antigenicity is shown once a bandcorresponding to the product exhibits reactivity at any of the dilutionsin the above range.

In an ELISA assay, the product to be screened is preferably used as thecoating antigen. A purified preparation is preferred, although a wholecell extract can also be used. Briefly, about 100 μl of a preparation atabout 10 μg protein/ml are distributed into wells of a 96-wellpolycarbonate ELISA plate. The plate is incubated for 2 hours at 37° C.then overnight at 4° C. The plate is washed with phosphate buffer saline(PBS) containing 0.05% Tween 20 (PBS/Tween buffer). The wells aresaturated with 250 μl PBS containing 1% bovine serum albumin (BSA) toprevent non-specific antibody binding. After 1 hour incubation at 37°C., the plate is washed with PBS/Tween buffer. The antiserum is seriallydiluted in PBS/Tween buffer containing 0.5% BSA. 100 μl of dilutions areadded per well. The plate is incubated for 90 minutes at 37° C., washedand evaluated according to standard procedures. For example, a goatanti-rabbit peroxidase conjugate is added to the wells when specificantibodies were raised in rabbits. Incubation is carried out for 90minutes at 37° C. and the plate is washed. The reaction is developedwith the appropriate substrate and the reaction is measured bycolorimetry (absorbance measured spectrophotometrically). Under theabove experimental conditions, a positive reaction is shown by O.D.values greater than a non-immune control serum.

In a dot blot assay, a purified product is preferred, although a wholecell extract can also be used. Briefly, a solution of the product atabout 100 μg/ml is serially two-fold diluted in 50 mM Tris-HCl (pH 7.5).100 μl of each dilution are applied to a nitrocellulose membrane 0.45 μmset in a 96-well dot blot apparatus (Biorad). The buffer is removed byapplying vacuum to the system. Wells are washed by addition of 50 mMTris-HCl (pH 7.5) and the membrane is air-dried. The membrane issaturated in blocking buffer (50 mM Tris-HCl (pH 7.5) 0.15 M NaCl, 10g/L skim milk) and incubated with an antiserum dilution from about 1:50to about 1:5000, preferably about 1:500. The reaction is revealedaccording to standard procedures. For example, a goat anti-rabbitperoxidase conjugate is added to the wells when rabbit antibodies areused. Incubation is carried out 90 minutes at 37° C. and the blot iswashed. The reaction is developed with the appropriate substrate andstopped. The reaction is measured visually by the appearance of acolored spot, e.g., by colorimetry. Under the above experimentalconditions, a positive reaction is shown once a colored spot isassociated with a dilution of at least about 1:5, preferably of at leastabout 1:500.

Therapeutic or prophylactic efficacy of a polypeptide or derivative ofthe invention can be evaluated as described below.

According to a seventh aspect of the invention, there is provided (i) acomposition of matter containing a polypeptide of the invention togetherwith a diluent or carrier; in particular, (ii) a pharmaceuticalcomposition containing a therapeutically or prophylactically effectiveamount of a polypeptide of the invention; (iii) a method for inducing animmune response against Chlamydia in a mammal, by administering to themammal an immunogenically effective amount of a polypeptide of theinvention to elicit an immune response, e.g., a protective immuneresponse to Chlamydia; and particularly, (iv) a method for preventingand/or treating a Chlamydia (e.g., C. trachomatis. C. psittaci, C.pneumotiiae, or C. pecorum) infection, by administering a prophylacticor therapeutic amount of a polypeptide of the invention to an individualin need. Additionally, the seventh aspect of the invention encompassesthe use of a polypeptide of the invention in the preparation of amedicament for preventing and/or treating Chlamydia infection.

The immunogenic compositions of the invention can be administered by anyconventional route in use in the vaccine field, in particular to amucosal (e.g., ocular, intranasal, pulmonary, oral, gastric; intestinal,rectal, vaginal, or urinary tract) surface or via the parenteral (e.g.,subcutaneous, intradermal, intramuscular, intravenous, orintraperitoneal) route. The choice of the administration route dependsupon a number of parameters, such as the adjuvant associated with thepolypeptide. For example, if a mucosal adjuvant is used, the intranasalor oral route will be preferred and if a lipid formulation or analuminum compound is used, the parenteral route will be preferred. Inthe latter case, the sub-cutaneous or intramuscular route is mostpreferred. The choice can also depend upon the nature of the vaccineagent. For example, a polypeptide of the invention fused to CTB or LTBwill be best administered to a mucosal surface.

A composition of the invention can contain one or several polypeptidesor derivatives of the invention. It can also contain at least oneadditional Chlamydia antigen, or a subunit, fragrment, homolog, mutant,or derivative thereof.

For use in a composition of the invention, a polypeptide or derivativethereof can be formulated into or with liposomes, preferably neutral oranionic liposomes, microspheres, ISCOMS, or virus-like-particles (VLPs)to facilitate delivery and/or enhance the immune response. Thesecompounds are readily available to one skilled in the art; for example,see Liposomes: A Practical Approach (supra).

Adjuvants other than liposomes and the like can also be used and areknown in the art. An appropriate selection can conventionally be made bythose skilled in the art, for example, from the list provided below.

Administration can be achieved in a single dose or repeated as necessaryat intervals as can be determined by one skilled in the art. Forexample, a priming dose can be followed by three booster doses at weeklyor monthly intervals. An appropriate dose depends on various parametersincluding the recipient (e.g., adult or infant), the particular vaccineantigen, the route and frequency of administration, the presence/absenceor type of adjuvant, and the desired effect (e.g., protection and/ortreatment), as can be determined by one skilled in the art. In general,a vaccine antigen of the invention can be administered by a mucosalroute in an amount from about 10 μg to about 500 mg, preferably fromabout 1 mg to about 200 mg. For the parenteral route of administration,the dose usually should not exceed about 1 mg, preferably about 100 μg.

When used as vaccine agents, polynucleotides and polypeptides of theinvention can be used sequentially as part of a multistep immunizationprocess. For example, a mammal can be initially primed with a vaccinevector of the invention such as a pox virus, e.g., via the parenteralroute, and then boosted twice with the polypeptide encoded by thevaccine vector, e.g., via the mucosal route. In another example,liposomes associated with a polypeptide or derivative of the inventioncan also be used for priming, with boosting being carried out mucosallyusing a soluble polypeptide or derivative of the invention incombination with a mucosal adjuvant (e.g., LT).

A polypeptide derivative of the invention is also useful as a diagnosticreagent for detecting the presence of anti-Chlamydia antibodies, e.g.,in a blood sample. Such polypeptides are about 5 to about 80, preferablyabout 10 to about 50 amino acids in length and can be labeled orunlabeled, depending upon the diagnostic method. Diagnostic methodsinvolving such a reagent are described below.

Upon expression of a DNA molecule of the invention, a polypeptide orpolypeptide derivative is produced and can be purified using knownlaboratory techniques. For example, the polypeptide or polypeptidederivative can be produced as a fusion protein containing a fused tailthat facilitates purification. The fusion product can be used toimmunize a small mammal, e.g., a mouse or a rabbit, in order to raiseantibodies against the polypeptide or polypeptide derivative(monospecific antibodies). The eighth aspect of the invention thusprovides a monospecific antibody that binds to a polypeptide orpolypeptide derivative of the invention.

By “monospecific antibody” is meant an antibody that is capable ofreacting with a unique naturally-occurring Chlamydia polypeptide. Anantibody of the invention can be polyclonal or monoclonal. Monospecificantibodies can be recombinant, e.g., chimeric (e.g., constituted by avariable region of murine origin associated with a human constantregion), humanized (a human immunoglobulin constant backbone togetherwith hypervariable region of animal, e.g., murine, origin), and/orsingle chain. Both polyclonal and monospecific antibodies can also be inthe form of immunoglobulin fragments, e.g., F(ab)′2 or Fab fragments.The antibodies of the invention can be of any isotype, e.g., IgG or IgA,and polyclonal antibodies can be of a single isotype or can contain amixture of isotypes.

The antibodies of the invention, which are raised to a polypeptide orpolypeptide derivative of the invention, can be produced and identifiedusing standard immunological assays, e.g., Western blot analysis, dotblot assay, or ELISA (see, e.g., Coligan et al., Current Protocols inImmunology (1994) John Wiley & Sons, Inc., New York, N.Y.). Theantibodies can be used in diagnostic methods to detect the presence of aChlamydia antigen in a sample, such as a biological sample. Theantibodies can also be used in affinity chromatography methods forpurifying a polypeptide or polypeptide derivative of the invention. Asis discussed further below, such antibodies can be used in prophylacticand therapeutic passive immunization methods.

Accordingly, a ninth aspect of the invention provides (i) a reagent fordetecting the presence of Chlamydia in a biological sample that containsan antibody, polypeptide, or polypeptide derivative of the invention;and (ii) a diagnostic method for detecting the presence of Chlamydia ina biological sample, by contacting the biological sample with anantibody, a polypeptide, or a polypeptide derivative of the invention,such that an immune complex is formed, and by detecting such complex toindicate the presence of Chlamydia in the sample or the organism fromwhich the sample is derived.

Those skilled in the art will understand that the immune complex isformed between a component of the sample and the antibody, polypeptide,or polypeptide derivative, whichever is used, and that any unboundmaterial can be removed prior to detecting the complex. As can be easilyunderstood, a polypeptide reagent is useful for detecting the presenceof anti-Chlamydia antibodies in a sample, e.g., a blood sample, while anantibody of the invention can be used for screening a sample, such as agastric extract or biopsy, for the presence of Chlamydia polypeptides.

For use in diagnostic applications, the reagent (i.e., the antibody,polypeptide, or polypeptide derivative of the invention) can be in afree state or immobilized on a solid support, such as a tube, a bead, orany other conventional support used in the field. Immobilization can beachieved using direct or indirect means. Direct means include passiveadsorption (non-covalent binding) or covalent binding between thesupport and the reagent. By “indirect means” is meant that ananti-reagent compound that interacts with a reagent is first attached tothe solid support. For example, if a polypeptide reagent is used, anantibody that binds to it can serve as an anti-reagent, provided that itbinds to an epitope that is not involved in the recognition ofantibodies in biological samples. Indirect means can also employ aligand-receptor system, for example, a molecule such as a vitamin can begrafted onto the polypeptide reagent and the corresponding receptor canbe immobilized on the solid phase. This is illustrated by thebiotin-streptavidin system. Alternatively, indirect means can be used,e.g., by adding to the reagent a peptide tail, chemically or by geneticengineering, and immobilizing the grafted or fused product by passiveadsorption or covalent linkage of the peptide tail.

According to a tenth aspect of the invention, there is provided aprocess for purifying, from a biological sample, a polypeptide orpolypeptide derivative of the invention, which involves carrying outantibody-based affinity chromatography with the biological sample,wherein the antibody is a monospecific antibody of the invention.

For use in a purification process of the invention, the antibody can bepolyclonal or monospecific, and preferably is of the IgG type. PurifiedIgGs can be prepared from an antiserum using standard methods (see,e.g., Coligan et al., supra). Conventional chromatography supports, aswell as standard methods for grafting antibodies, are disclosed in,e.g., Antibodies: A Laboratory Manual, D. Lane, E. Harlow, Eds. (1988).

Briefly, a biological sample, such as an C. pneumoniae extract,preferably in a buffer solution, is applied to a chromatographymaterial, preferably equilibrated with the buffer used to dilute thebiological sample so that the polypeptide or polypeptide derivative ofthe invention (i.e., the antigen) is allowed to adsorb onto thematerial. The chromatography material, such as a gel or a resin coupledto an antibody of the invention, can be in batch form or in a column.The unbound components are washed off and the antigen is then elutedwith an appropriate elution buffer, such as a glycine buffer or a buffercontaining a chaotropic agent, e.g., guanidine HCl, or high saltconcentration (e.g., 3 M MgCl₂). Eluted fractions are recovered and thepresence of the antigen is detected, e.g., by measuring the absorbanceat 280 nm.

An antibody of the invention can be screened for therapeutic efficacy asdescribed as follows. According to an eleventh aspect of the invention,there is provided (i) a composition of matter containing a monospecificantibody of the invention, together with a diluent or carrier; (ii) apharmaceutical composition containing a therapeutically orprophylactically effective amount of a monospecific antibody of theinvention, and (iii) a method for treating or preventing a Chlamydia(e.g., C. trachomatis, C. psittaci, C. pneumoniae or C. pecorum)infection, by administering a therapeutic or prophylactic amount of amonospecific antibody of the invention to an individual in need.Additionally, the eleventh aspect of the invention encompasses the useof a monospecific antibody of the invention in the preparation of amedicament for treating or preventing Chlamydia infection.

To this end, the monospecific antibody can be polyclonal or monoclonal,preferably of the IgA isotype (predominantly). In passive immunization,the antibody can be administered to a mucosal surface of a mammal, e.g.,the gastric mucosa, e.g., orally or intragastrically, advantageously, inthe presence of a bicarbonate buffer. Alternatively, systemicadministration, not requiring a bicarbonate buffer, can be carried out.A monospecific antibody of the invention can be administered as a singleactive component or as a mixture with at least one monospecific antibodyspecific for a different Chlamydia polypeptide. The amount of antibodyand the particular regimen used can be readily determined by one skilledin the art. For example, daily administration of about 100 to 1,000 mgof antibodies over one week, or three doses per day of about 100 to1,000 mg of antibodies over two or three days, can be an effectiveregimens for most purposes.

Therapeutic or prophylactic efficacy can be evaluated using standardmethods in the art, e.g., by measuring induction of a mucosal immuneresponse or induction of protective and/or therapeutic immunity, using,e.g., the C. pneumoniae mouse model . Those skilled in the art willrecognize that the C. pneumoniae strain of the model can be replacedwith another Chlamydia strain. For example, the efficacy of DNAmolecules and polypeptides from C. pneumoniae is preferably evaluated ina mouse model using an C. pneumoniae strain. Protection can bedetermined by comparing the degree of Chlamydia infection to that of acontrol group. Protection is shown when infection is reduced bycomparison to the control group. Such an evaluation can be made forpolynucleotides, vaccine vectors, polypeptides and derivatives thereof,as well as antibodies of the invention.

Adjuvants useful in any of the vaccine compositions described above areas follows.

Adjuvants for parenteral administration include aluminum compounds, suchas aluminum hydroxide, aluminum phosphate, and aluminum hydroxyphosphate. The antigen can be precipitated with, or adsorbed onto, thealuminum compound according to standard protocols. Other adjuvants, suchas RIBI (ImmunoChem, Hamilton, Mont.), can be used in parenteraladministration.

Adjuvants for mucosal administration include bacterial toxins, e.g., thecholera toxin (CT), the E. coli heat-labile toxin (LT), the Clostridiumdifficile toxin A and the pertussis toxin (PT), or combinations,subunits, toxoids, or mutants thereof. For example, a purifiedpreparation of native cholera toxin subunit B (CTB) can be of use.Fragments, homologs, derivatives, and fusions to any of these toxins arealso suitable, provided that they retain adjuvant activity. Preferably,a mutant having reduced toxicity is used. Suitable mutants aredescribed, e.g., in WO 95/17211 (Arg-7-Lys CT mutant), WO 96/6627(Arg-192-Gly LT mutant), and WO 95/34323 (Arg-9-Lys and Glu-129-Gly PTmutant). Additional LT mutants that can be used in the methods andcompositions of the invention include, e.g., Ser-63-Lys, Ala-69-Gly,Glu-110-Asp, and Glu-112-Asp mutants. Other adjuvants, such as abacterial monophosphoryl lipid A (MPLA) of, e.g., E. coli, Salmonellaminnesota, Salmonella typhimurium, or Shigella flexneri; saponins, orpolylactide glycolide (PLGA) microspheres, can also be used in mucosaladministration.

Adjuvants useful for both mucosal and parenteral administrations includepolyphosphazene (WO 95/2415), DC-chol (3 b-(N-(N′,N′-dimethylaminomethane)-carbamoyl) cholesterol; U.S. Pat. No. 5,283,185 and WO96/14831) and QS-21 (WO 88/9336).

Any pharmaceutical composition of the invention, containing apolynucleotide, a polypeptide, a polypeptide derivative, or an antibodyof the invention, can be manufactured in a conventional manner. Inparticular, it can be formulated with a pharmaceutically acceptablediluent or carrier, e.g., water or a saline solution such as phosphatebuffer saline. In general, a diluent or carrier can be selected on thebasis of the mode and route of administration, and standardpharmaceutical practice. Suitable pharmaceutical carriers or diluents,as well as pharmaceutical necessities for their use in pharmaceuticalformulations, are described in Remington's Pharmaceutical Sciences, astandard reference text in this field and in the USP/NF.

The invention also includes methods in which Chlamydia infection, aretreated by oral administration of a Chlamydia polypeptide of theinvention and a mucosal adjuvant, in combination with an antibiotic, anantacid, sucralfate, or a combination thereof. Examples of suchcompounds that can be administered with the vaccine antigen and theadjuvant are antibiotics, including, e.g., macrolides, tetracyclines,and derivatives thereof (specific examples of antibiotics that can beused include azithromycin or doxicyclin or immunomodulators such ascytokines or steroids. In addition, compounds containing more than oneof the above-listed components coupled together, can be used. Theinvention also includes compositions for carrying out these methods,i.e., compositions containing a Chlamydia antigen (or antigens) of theinvention, an adjuvant, and one or more of the above-listed compounds,in a pharmaceutically acceptable carrier or diluent.

Amounts of the above-listed compounds used in the methods andcompositions of the invention can readily be determined by one skilledin the art. In addition, one skilled in the art can readily designtreatment/immunization schedules. For example, the non-vaccinecomponents can be administered on days 1-14, and the vaccineantigen+adjuvant can be administered on days 7, 14, 21, and 28.

The above disclosure generally describes the present invention. A morecomplete understanding can be obtained by reference to the followingspecific examples. These examples are described solely for purposes ofillustration and are not intended to limit the scope of the invention.Changes in form and substitution of equivalents are contemplated ascircumstances may suggest or render expedient. Although specific termshave been employed herein, such terms are intended in a descriptivesense and not for purposes of limitation.

EXAMPLE 1 Preparation of Plasmid Vector pCAI556 Containing the lorf2Gene

This example illustrates the preparation of a plasmid vector pCAI556containing the lorf2 gene.

The lorf2 gene was amplified from Chlamydia pneumoniae genomic DNA bypolymerase chain reaction (PCR) using a 5′ primer:

(5′ ATAAGAATGCGGCCGCCACCATGTCAGGATACGCTGAACTTCC 3′)

(SEQ ID NO: 3), which contains a Not I restriction site, a ribosomebinding site, an initiation codon and a sequence close to the 5′ end ofthe lorf2 coding sequence, and a 3′ primer:

(5′ GCGCCGGATCCCAAACGCTGAAATTATACCTA 3′)

(SEQ ID NO: 4). The 3′ primer includes the sequence encoding theC-terminal sequence of the lorf2 gene and a Bam HI restriction site. Thestop codon was excluded and an additional nucleotide was inserted toobtain an in-frame fusion with the Histidine tag.

After amplification, the PCR fragment was purified using QIAquick™ PCRpurification kit (Qiagen) and then digested with Not I and Bam HI andcloned into the pCA-Myc-His eukaryotic expression vector describe inExample 2 (FIG. 3) with transcription under control of the human CMVpromoter.

EXAMPLE 2 Preparation of the Eukaryotic Expression Vector pCA/MYC-HIS

This example illustrates the preparation of the eukaryotic expressionvector pCA/Myc-His.

Plasmid pcDNA3.1(−)Myc-His C (Invitrogen) was restricted with Spe I andBam HI to remove the CMV promoter and the remaining vector fragment wasisolated. The CMV promoter and intron A from plasmid VR-1012 (Vical) wasisolated on a Spe I/Bam HI fragment. The fragments were ligated togetherto produce plasmid pCA/Myc-His. The Not I/Bam HI restricted PCR fragmentcontaining the lorf2 gene was ligated into the Not I and Bam HIrestricted plasmid pCA/Myc-His to produce plasmid pCAI556 (FIG. 3).

The resulting plasmid, pCAI556, was transfered by electroporation intoE. coli XL-1 blue (Stratagene) which was grown in LB broth containing 50μg/ml of carbenicillin. The plasmid was isolated by Endo Free PlasmidGiga Kit™ (Qiagen) large scale DNA purification system. DNAconcentration was determined by absorbance at 260 nm and the plasmid wasverified after gel electrophoresis and Ethidium bromide staining andcomparison to molecular weight standards. The 5′ and 3′ ends of the genewere verified by sequencing using a LiCor model 4000 L DNA sequencer andIRD-800 labelled primers.

EXAMPLE 3 Protection Against Intranasal C. pneumoniae

This example illustrates the immunization of mice to achieve protectionagainst an intranasal challenge of C. pneumoniae.

It has been previously demonstrated (Yang et. al., 1993) that mice aresusceptible to intranasal infection with different isolates of C.pneumoniae. Strain AR-39 (Grayston, 1989) was used in Balb/c mice as achallenge infection model to examine the capacity of chlamydia geneproducts delivered as naked DNA to elicit a protective response againsta sublethal C. pneumoniae lung infection. Protective immunity is definedas an accelerated clearance of pulmonary infection.

Groups of 7 to 9 week old male Balb/c mice (8 to 10 per group) wereimmunized intramuscularly (i.m.) plus intranasally (i.n.) with plasmidDNA containing the coding sequence of C. pneumoniae lorf2 gene asdescribed in Examples 1 and 2. Saline or the plasmid vector lacking aninserted chlamydial gene was given to groups of control animals.

For i.m. immunization alternate left and right quadriceps were injectedwith 100 μg of DNA in 50 μl of PBS on three occasions at 0, 3 and 6weeks. For i.n. immunization, anaesthetized mice aspirated 50 μl of PBScontaining 50 μg DNA on three occasions at 0, 3 and 6 weeks. At week 8,immunized mice were inoculated i.n. with 5×10⁵ IFU of C. pneumoniae,strain AR39 in 100 μl of SPG buffer to test their ability to limit thegrowth of a sublethal C. pneumoniae challenge.

Lungs were taken from mice at day 9 post-challenge and immediatelyhomogenised in SPG buffer (7.5% sucrose, 5 mM glutamate, 12.5 mMphosphate pH 7.5). The homogenate was stored frozen at −70° C. untilassay. Dilutions of the homogenate were assayed for the presence ofinfectious chlamydia by inoculation onto monolayers of susceptiblecells. The inoculum was centriftiged onto the cells at 3000 rpm for 1hour, then the cells were incubated for three days at 35° C. in thepresence of 1 μg/ml cycloheximide. After incubation the monolayers werefixed with formalin and methanol then immunoperoxidase stained for thepresence of chlamydial inclusions using convalescent sera from rabbitsinfected with C. pneumoniae and metal-enhanced DAB as a peroxidasesubstrate.

FIG. 4 and Table 1 show that mice immunized i.n. and i.m. with pCAI556had chlamydial lung titers less than 18,000 EFU/lung (mean 11,050) in 6of 6 cases at day 9 whereas the range of values for control mice shamimmunized with saline were 10,700-458,000 IFU/lung (mean 111,783) at day9. DNA immunisation per se was not responsible for the observedprotective effect since another plasmid DNA construct, pCAI624, failedto protect, with lung titers in immunized mice similar (134,600IFU/lung) to those obtained for saline-immunized control mice. Theconstruct pCAI624 is identical to pCAI556 except that the nucleotidesequence encoding the lorf2 gene is replaced with a C. pneumoniaenucleotide sequence encoding a different a 98 kDa outer membraneprotein.

TABLE 1 Bacterial Load (Inclusion-Forming Units per Lung) in the Lungsof BALB/C Mice Immunized with Various DNA Immunization ConstructsImmunizing Construct Saline pCAI624 pCAI556 Mouse Day 9 Day 9 Day 9  128300 70200 11300  2 478800 206500 9100  3 201300 76900 17200  4 133600209700 16200  5 23700 41200 6400  6 35900 203100 6100  7 108800  8 64700 9 68800 10 18200 11 59500 12 41700 13 87000 14 75000 15 118900 16144300 17 247000 18 132000 19 207400 20 87500 21 81200 22 72800 23 1070024 155700 MEAN 111783.3 134600 11050 SD 100055.3 79626.73 4781.95Wilcoxon p 0.3642 0.000383

Equivalents

From the foregoing detailed description of the specific embodiments ofthe invention, it should be apparent that a unique Chlamydia antigen hasbeen described. Although particular embodiments have been disclosedherein in detail, this has been done by way of example for purposes ofillustration only, and is not intended to be limiting with respect tothe scope of the appended claims which follow. In particular, it iscontemplated by the inventor that various substitutions, alterations,and modifications may be made to the invention without departing fromthe spirit and scope of the invention as defined by the claims.

5 1 1550 DNA Homo sapiens CDS (101)..(1366) 1 atgtttgttt cttgtagctcagtcgctttc ttttagcttt aagttttgat agcctgcttg 60 gtcttctgtt tctacacttaatattgatac taaggatact atg aaa aaa cag gta 115 Met Lys Lys Gln Val 1 5tat caa tgg tta gcg agt gtg gtt ctt tta gcg ctg aca att tca gga 163 TyrGln Trp Leu Ala Ser Val Val Leu Leu Ala Leu Thr Ile Ser Gly 10 15 20 tacgct gaa ctt cct ctc tcg gaa caa aaa gta aaa agt cac act tat 211 Tyr AlaGlu Leu Pro Leu Ser Glu Gln Lys Val Lys Ser His Thr Tyr 25 30 35 aca acttta gac gaa gtc aaa gac tac tta agt aaa cgg ggt ttt gta 259 Thr Thr LeuAsp Glu Val Lys Asp Tyr Leu Ser Lys Arg Gly Phe Val 40 45 50 gaa acg cgaaag caa gat ggc gtt tta aga ata gca gga gat gtt aga 307 Glu Thr Arg LysGln Asp Gly Val Leu Arg Ile Ala Gly Asp Val Arg 55 60 65 gcc cgg tgg ttgtat ttc aga gaa gat atc aaa aac ccc tca gat aaa 355 Ala Arg Trp Leu TyrPhe Arg Glu Asp Ile Lys Asn Pro Ser Asp Lys 70 75 80 85 gat aaa tac aatccc tta cca gta aat cgt tat cgt agt gaa ttt tat 403 Asp Lys Tyr Asn ProLeu Pro Val Asn Arg Tyr Arg Ser Glu Phe Tyr 90 95 100 ctc tat att gattat cgc gct gag agg aac tgg ctg tct tca aag atg 451 Leu Tyr Ile Asp TyrArg Ala Glu Arg Asn Trp Leu Ser Ser Lys Met 105 110 115 aat tgg aca gcaatt gca gga ggg gaa aac act gca gct ggt gtt gat 499 Asn Trp Thr Ala IleAla Gly Gly Glu Asn Thr Ala Ala Gly Val Asp 120 125 130 atc aac aga gcattt cta gga tat cgt ttt tat aag aat ccc gaa aca 547 Ile Asn Arg Ala PheLeu Gly Tyr Arg Phe Tyr Lys Asn Pro Glu Thr 135 140 145 cgt aca gat ttcttt atg gaa atc gga cgt tct ggt tta gga gat ctc 595 Arg Thr Asp Phe PheMet Glu Ile Gly Arg Ser Gly Leu Gly Asp Leu 150 155 160 165 ttt gag tcagaa gtc caa ttc caa agt aat ttt gac gga cta cat ata 643 Phe Glu Ser GluVal Gln Phe Gln Ser Asn Phe Asp Gly Leu His Ile 170 175 180 tat tgg actcga gaa ctt tct aag gac tat cct tat caa gtg att gtt 691 Tyr Trp Thr ArgGlu Leu Ser Lys Asp Tyr Pro Tyr Gln Val Ile Val 185 190 195 cat gga ggtcct ttc gtc gtg aac atg aca aaa aaa cat tat gct tgg 739 His Gly Gly ProPhe Val Val Asn Met Thr Lys Lys His Tyr Ala Trp 200 205 210 gtt gta gaaggg att ctc aat cgt ttg cct aaa cag ttt ttt gtg aaa 787 Val Val Glu GlyIle Leu Asn Arg Leu Pro Lys Gln Phe Phe Val Lys 215 220 225 tgt agt gttgtc gac tgg aac aca ttc gtt cct tca gaa acc tcc act 835 Cys Ser Val ValAsp Trp Asn Thr Phe Val Pro Ser Glu Thr Ser Thr 230 235 240 245 aca gaaaaa gct gct aca aac gct atg aaa tac aaa tac tgt gtt tgg 883 Thr Glu LysAla Ala Thr Asn Ala Met Lys Tyr Lys Tyr Cys Val Trp 250 255 260 cag tggctc gtc gga aag cat agt cag gtt cct tgg atc aat gga cag 931 Gln Trp LeuVal Gly Lys His Ser Gln Val Pro Trp Ile Asn Gly Gln 265 270 275 aaa aagcct cta tat ctt tat gga gct ttc tta atg aac cct tta gca 979 Lys Lys ProLeu Tyr Leu Tyr Gly Ala Phe Leu Met Asn Pro Leu Ala 280 285 290 aag gctacg aag act acg tta aat gga aaa gaa aac cta gct tgg ttt 1027 Lys Ala ThrLys Thr Thr Leu Asn Gly Lys Glu Asn Leu Ala Trp Phe 295 300 305 att ggagga act tta ggg gga ctc aga aaa gct gga gac tgg tct gcc 1075 Ile Gly GlyThr Leu Gly Gly Leu Arg Lys Ala Gly Asp Trp Ser Ala 310 315 320 325 acagta cgt tat gag tat gtc gaa gcc ttg tcg gtt cca gaa ata gat 1123 Thr ValArg Tyr Glu Tyr Val Glu Ala Leu Ser Val Pro Glu Ile Asp 330 335 340 gtttca ggg att ggc cgt ggt aat tta tta aag ttt tgg ttc gcc caa 1171 Val SerGly Ile Gly Arg Gly Asn Leu Leu Lys Phe Trp Phe Ala Gln 345 350 355 gcaatt gct gct aac tat gat cct aaa gag gct aat ggt ttt aca aat 1219 Ala IleAla Ala Asn Tyr Asp Pro Lys Glu Ala Asn Gly Phe Thr Asn 360 365 370 tataaa gga ttt tcc gct cta tat atg tat ggc atc aca gat tct cta 1267 Tyr LysGly Phe Ser Ala Leu Tyr Met Tyr Gly Ile Thr Asp Ser Leu 375 380 385 tcattc aga gct tat ggg gct tac tcc aaa cca gca aac gat aaa ctc 1315 Ser PheArg Ala Tyr Gly Ala Tyr Ser Lys Pro Ala Asn Asp Lys Leu 390 395 400 405ggc agt gat ttt act ttc cga aag ttt gat cta ggt ata att tca gcg 1363 GlySer Asp Phe Thr Phe Arg Lys Phe Asp Leu Gly Ile Ile Ser Ala 410 415 420ttt taagtcaaat tttaataaaa tctttaaaaa caggctcgca ttaattatta 1416 Phegtgagagctt tttttttatt ttttataata aaactaaaag atttttatta ttttttgagt 1476ttttatggtt aatcctattg gtccaggtcc tatagacgaa acagaacgca cacctcccgc 1536agatctttct gctc 1550 2 422 PRT Homo sapiens 2 Met Lys Lys Gln Val TyrGln Trp Leu Ala Ser Val Val Leu Leu Ala 1 5 10 15 Leu Thr Ile Ser GlyTyr Ala Glu Leu Pro Leu Ser Glu Gln Lys Val 20 25 30 Lys Ser His Thr TyrThr Thr Leu Asp Glu Val Lys Asp Tyr Leu Ser 35 40 45 Lys Arg Gly Phe ValGlu Thr Arg Lys Gln Asp Gly Val Leu Arg Ile 50 55 60 Ala Gly Asp Val ArgAla Arg Trp Leu Tyr Phe Arg Glu Asp Ile Lys 65 70 75 80 Asn Pro Ser AspLys Asp Lys Tyr Asn Pro Leu Pro Val Asn Arg Tyr 85 90 95 Arg Ser Glu PheTyr Leu Tyr Ile Asp Tyr Arg Ala Glu Arg Asn Trp 100 105 110 Leu Ser SerLys Met Asn Trp Thr Ala Ile Ala Gly Gly Glu Asn Thr 115 120 125 Ala AlaGly Val Asp Ile Asn Arg Ala Phe Leu Gly Tyr Arg Phe Tyr 130 135 140 LysAsn Pro Glu Thr Arg Thr Asp Phe Phe Met Glu Ile Gly Arg Ser 145 150 155160 Gly Leu Gly Asp Leu Phe Glu Ser Glu Val Gln Phe Gln Ser Asn Phe 165170 175 Asp Gly Leu His Ile Tyr Trp Thr Arg Glu Leu Ser Lys Asp Tyr Pro180 185 190 Tyr Gln Val Ile Val His Gly Gly Pro Phe Val Val Asn Met ThrLys 195 200 205 Lys His Tyr Ala Trp Val Val Glu Gly Ile Leu Asn Arg LeuPro Lys 210 215 220 Gln Phe Phe Val Lys Cys Ser Val Val Asp Trp Asn ThrPhe Val Pro 225 230 235 240 Ser Glu Thr Ser Thr Thr Glu Lys Ala Ala ThrAsn Ala Met Lys Tyr 245 250 255 Lys Tyr Cys Val Trp Gln Trp Leu Val GlyLys His Ser Gln Val Pro 260 265 270 Trp Ile Asn Gly Gln Lys Lys Pro LeuTyr Leu Tyr Gly Ala Phe Leu 275 280 285 Met Asn Pro Leu Ala Lys Ala ThrLys Thr Thr Leu Asn Gly Lys Glu 290 295 300 Asn Leu Ala Trp Phe Ile GlyGly Thr Leu Gly Gly Leu Arg Lys Ala 305 310 315 320 Gly Asp Trp Ser AlaThr Val Arg Tyr Glu Tyr Val Glu Ala Leu Ser 325 330 335 Val Pro Glu IleAsp Val Ser Gly Ile Gly Arg Gly Asn Leu Leu Lys 340 345 350 Phe Trp PheAla Gln Ala Ile Ala Ala Asn Tyr Asp Pro Lys Glu Ala 355 360 365 Asn GlyPhe Thr Asn Tyr Lys Gly Phe Ser Ala Leu Tyr Met Tyr Gly 370 375 380 IleThr Asp Ser Leu Ser Phe Arg Ala Tyr Gly Ala Tyr Ser Lys Pro 385 390 395400 Ala Asn Asp Lys Leu Gly Ser Asp Phe Thr Phe Arg Lys Phe Asp Leu 405410 415 Gly Ile Ile Ser Ala Phe 420 3 43 DNA Artificial SequenceDescription of Artificial Sequence PCR Primer Sequence 3 ataagaatgcggccgccacc atgtcaggat acgctgaact tcc 43 4 32 DNA Artificial SequenceDescription of Artificial Sequence PCR Primer Sequence 4 gcgccggatcccaaacgctg aaattatacc ta 32 5 1550 DNA Homo sapiens 5 tacaaacaaagaacatcgag tcagcgaaag aaaatcgaaa ttcaaaacta tcggacgaac 60 cagaagacaaagatgtgaat tataactatg attcctatga tacttttttg tccatatagt 120 taccaatcgctcacaccaag aaaatcgcga ctgttaaagt cctatgcgac ttgaaggaga 180 gagccttgtttttcattttt cagtgtgaat atgttgaaat ctgcttcagt ttctgatgaa 240 ttcatttgccccaaaacatc tttgcgcttt cgttctaccg caaaattctt atcgtcctct 300 acaatctcgggccaccaaca taaagtctct tctatagttt ttggggagtc tatttctatt 360 tatgttagggaatggtcatt tagcaatagc atcacttaaa atagagatat aactaatagc 420 gcgactctccttgaccgaca gaagtttcta cttaacctgt cgttaacgtc ctcccctttt 480 gtgacgtcgaccacaactat agttgtctcg taaagatcct atagcaaaaa tattcttagg 540 gctttgtgcatgtctaaaga aataccttta gcctgcaaga ccaaatcctc tagagaaact 600 cagtcttcaggttaaggttt cattaaaact gcctgatgta tatataacct gagctcttga 660 aagattcctgataggaatag ttcactaaca agtacctcca ggaaagcagc acttgtactg 720 tttttttgtaatacgaaccc aacatcttcc ctaagagtta gcaaacggat ttgtcaaaaa 780 acactttacatcacaacagc tgaccttgtg taagcaagga agtctttgga ggtgatgtct 840 ttttcgacgatgtttgcgat actttatgtt tatgacacaa accgtcaccg agcagccttt 900 cgtatcagtccaaggaacct agttacctgt ctttttcgga gatatagaaa tacctcgaaa 960 gaattacttgggaaatcgtt tccgatgctt ctgatgcaat ttaccttttc ttttggatcg 1020 aaccaaataacctccttgaa atccccctga gtcttttcga cctctgacca gacggtgtca 1080 tgcaatactcatacagcttc ggaacagcca aggtctttat ctacaaagtc cctaaccggc 1140 accattaaataatttcaaaa ccaagcgggt tcgttaacga cgattgatac taggatttct 1200 ccgattaccaaaatgtttaa tatttcctaa aaggcgagat atatacatac cgtagtgtct 1260 aagagatagtaagtctcgaa taccccgaat gaggtttggt cgtttgctat ttgagccgtc 1320 actaaaatgaaaggctttca aactagatcc atattaaagt cgcaaaattc agtttaaaat 1380 tattttagaaatttttgtcc gagcgtaatt aataatcact ctcgaaaaaa aaataaaaaa 1440 tattattttgattttctaaa aataataaaa aactcaaaaa taccaattag gataaccagg 1500 tccaggatatctgctttgtc ttgcgtgtgg agggcgtcta gaaagacgag 1550

What is claimed is:
 1. An isolated polynucleotide comprising apolynucleotide from a strain of Chlamydia, selected from the groupconsisting of: (a) a polynucleotide comprising the nucleotide sequenceof SEQ ID NO: 1; and (b) a polynucleotide which hybridizes understringent hybridizing conditions of 6×SSC containing 50% formamide at42° C. with a polynucleotide that has a complementary sequence to thefull length of: SEQ ID NO: 1, the coding sequence of SEQ ID NO: 1, orthe open reading frame(s) of SEQ ID NO: 1; wherein said isolatedpolynucleotide, when administered in an immunogenically-effective amountto a mammal, induces an immune response by said mammal againstChlamydia.
 2. The polynucleotide of claim 1, linked to a secondnucleotide sequence encoding a fusion polypeptide.
 3. The polynucleotideof claim 2 wherein the fusion polypeptide is a heterologous signalpeptide.
 4. The polynucleotide of claim 2 wherein the polynucleotideencodes a polypeptide comprising the amino acid sequence of the SEQ IDNO:
 2. 5. An expression cassette, comprising the polynucleotide of claim1 operably linked to a promoter.
 6. An expression vector, comprising theexpression cassette of claim
 5. 7. A host cell, comprising theexpression cassette of claim
 5. 8. The host cell of claim 5, whereinsaid host cell is a prokaryotic cell.
 9. The host cell of claim 5,wherein said host cell is a eukaryotic cell.
 10. A method for producinga recombinant polypeptide comprising the amino acid sequence of havingSEQ ID NO: 2, comprising: (a) culturing a host cell of claim 7, underconditions that the allow the expression of the polypeptide; and (b)recovering the recombinant polypeptide.